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Abstract

Our ability to control malaria has been challenged by increasing antimalarial
resistance. Plasmodium falciparum undergoes dormancy in the blood stages which is
hypothesized to be a means by which they are able to survive under drug pressure. This
helps select for resistant parasites which grow following removal of drug. The
mechanisms behind dormancy and the subsequent recrudescence are not fully
understood but translating knowledge from related organisms which undergo a similar
phenomenon might shed some light. Higher plants utilize dormancy during the early
development stages to survive under unfavorable conditions, increasing fitness of the
seedling and ensuring viability when this is released and it develops into a mature plant.
Abscisic acid (ABA) and gibberellic acid (GA) antagonistically regulate this in response to
environmental

cues.

We

have

found

that

both

can

be

supplemented

to

dihydroartemesinin-induced dormant parasites to stimulate early recovery. Fluridone, an
ABA inhibitor that releases dormancy in plants, was found to prolong it and cause a delay
in recrudescence. These effects were observed in artemisinin sensitive and resistant
strains.
The apicoplast is required for recovery and supplementation of essential
isoprenoid, isopentyl pyrophosphate (IPP), in apicoplast deficient parasites is sufficient
enough to compensate for the lack of the organelle in antibiotic treated parasites. IPP
plays an important role in development and metabolism of blood stage parasites as a key

viii

component of numerous secondary metabolites and protein activity by prenylation of
isoprenoids. Its role in dormancy has not been explored prior to this study.
Carotenoids are long-chained ABA precursors consisting of two molecules of
geranylgeranyl pyrophosphate (GGPP). Several carotenoids as well as enzymes in that
pathway have been identified in the blood stages of P. falciparum. The Apicomplexan
parasite, Toxoplasma gondii synthesizes ABA, where it plays a role in signaling and
development. To date ABA has not been detected in P. falciparum due to limitations in
methods previously utilized. We have found that parasites with fosmidomycin inhibition of
isoprenoids can be rescued with GGPP supplementation which we planned to use to
further elucidate the carotenoid biosynthetic pathway.
We hypothesized that Plasmodium has retained the ability to biosynthesize ABA
and aimed to confirm this. We developed a novel method to label GGPP with 13C on three
of its isoprene units. This would be used to metabolically label isoprenoid inhibited P.
falciparum for incorporation through the carotenoid pathway for detection of 13C-ABA.

ix

Chapter 1
Introduction
Malaria: Overview
Malaria is a parasitic disease thought to be considered the most important one to
man. The disease is caused by the obligate intracellular protozoa of the genus
Plasmodium, belonging to the phylum Apicomplexa. Malaria parasites infect a variety of
vertebrate intermediate hosts including mammals, birds and reptiles [1]. Six species are
known to cause disease in humans: Plasmodium falciparum, P. vivax, P. ovale, P.
malariae, P. knowelsi and more recently, P. cynomolgi [2, 3]. The latter is an emerging
zoonotic species that transmits the disease between man and macaque monkey [4]. P.
falciparum is responsible for the most severe form, contributing to most morbidity and
worldwide mortality associated with the disease. Other single-celled eukaryotes in the
phylum Apicomplexa include Toxoplasma, Cryptosporidium, Gregarinia and Babesia [5].
These organisms share an apical polar ring, apical complex and most but not all have an
apicoplast. The apical complex is a defining feature that includes a series of microtubules,
rhoptries and micronemes near the anterior end of the cell and is involved in host cell
invasion [6, 7].

History
Historical records of malaria infections date back to Chinese documents from
around 2700 BC and evidence exists in other geographical texts and art over several
1

millennia [8]. The name derives from the Italian term “mal’aria” which translates to “bad
air” due to the misconception that the disease originated from swamp fumes [9]. The
modern discovery and identification of malaria as we know it today, began in 1880 when
Charles Louis Alphonse Laveran, a French military doctor, identified pigmented
unicellular parasites in blood smears as well as observed exflagellation of a gametocyte
[10]. He named this parasite Oscillaria malariae and also noticed that the drug quinine
eliminated it in blood. He was awarded the Nobel Prize in 1907 for his work despite initial
skepticism from the scientific community that believed his discovery was of bacterial origin
before it was proven to be parasitic. In 1885 Camillo Golgi, an Italian neurophysiologist,
identified tertian and quartan malaria, which had symptomatic fevers reoccurring every
48 and 72 hours respectively [11]. This discovery was a clue that malaria could be caused
by different species of Plasmodium which had varying life cycles. Ronald Ross, a British
military doctor, was key in the discovery of parasite to host transmission. In 1897, he
discovered Plasmodium oocysts in mosquito midguts and suggested that mosquitos were
the vector that transmitted disease to humans. He received the Nobel Prize in 1902. In
1899, Giovanni Grassi and Amico Bignami not only demonstrated that only female
Anopheles mosquitos transmitted malaria, but characterized the life cycles of P. vivax, P.
malariae and P. falciparum [8]. A significant breakthrough occurred in 1976 when William
Trager and J.B. Jensen developed a method for continuous culture of blood stage
parasites which revolutionized malaria research [12]. Through the work done by these
early researchers and many others, we would discover so much more about the parasite,
disease and interactions with humans.
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Plasmodium spp. life cycle
Exoerythocytic stage
The Plasmodium life cycle is complex and is differentiated into three distinct stages
(Figure 1.1). The two asexual stages occur in the human intermediate host with the final
sexual stage occurring in its definitive host, an Anopheles mosquito, which consists of
about 30-40 species that transmit malaria [13]. Most P. falciparum infections are
transmitted by A. gambiae. The exoerythrocytic stage begins when an infected female
mosquito takes a blood meal. Sporozoites from the salivary glands are inoculated through
the epidermis into the blood stream where they make their way through hepatic tissue.
They pass through a Kupffer cell, specialized macrophages in the liver, and use their
surface circumsporozoite protein (CSP) to bind and invade a hepatocyte [14]. These
undergo several rounds of replication as they multiply and develop into hepatic schizonts.
These grow and produce merozoites which upon rupture will enter the blood stream,
taking anywhere from 6 to 10 days.

Erythrocytic stage
The erythrocytic stage begins when a merozoite originating from a hepatic schizont
invades a red blood cell. This occurs because merozoites cannot replicate outside a host
cell. Contact with a red blood cell is initiated by merozoite surface proteins (MSP), apical
membrane antigen-1 and erythrocyte binding antigen-175 which bind to surface receptors
on the red blood cell [15-17]. This process will allow the apical end of the merozoite to
reorient itself allowing the secretory organelles to form a junction that allows for rapid
entry [18]. A small form known as a ring (0-24 hours) develops and as it matures, it
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becomes a trophozoite (24-36 hours) [19]. Most metabolic activity occurs in this stage,
including DNA synthesis, replication and protein translation. Rapid development occurs
marked by morphological changes and multiplication into a schizont (40-48 hours),
bearing 16-32 merozoites that will rupture and invade new erythrocytes to perpetuate this
cycle. This cycle lasts about 44-48 hours in most strains of P. falciparum, P. vivax and P.
ovale. The cycle of P. malariae is 72 hours and 24 hours for P. knowlesi [3].

Sporogonic cycle
Some blood stage parasites may differentiate into the sexual forms: male
microgametocytes or female macrogametocytes. These have five stages of development
marked by morphological changes resembling trophozoites in stage I to a sickle or
banana shape forms by stage V [20]. These are ingested by a feeding female mosquito
taking a blood meal. Within its midgut, these will differentiate into gametes. Male
microgametes will exflagellate and fertilize female macrogametes to form a zygote [21].
This stage is diploid where sexual recombination of genetic material occurs. The zygote
will mature into an ookinete which penetrates the midgut and becomes an oocyst. This
stage houses the sporozoites that are found in mosquito salivary glands which will go on
to infect new hosts. This entire process can take up to 12 days.

Plasmodium genome
The Plasmodium nuclear genome was annotated in 2002 using reference strain
3D7, which was cloned from NF54, an isolate from obtained from a Netherlands airport
[22]. This genome is 22.9 mega bases (Mb) with 14 chromosomes, 5269 genes and about
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80 gaps. It is unique in that it is primarily adenine+thymine (A+T) rich (~ 80.6%). Parasites
contain two additional genomes. The apicoplast organelle contains a 35 kilobase (kb)
circular genome and the mitochondrion contains a 6 kb linear genome, that encodes three
protein genes and large and small subunit ribosomal RNA genes [23].

Symptoms and diagnosis
Uncomplicated malaria
Uncomplicated malaria occurs in patients that are symptomatic but show no signs
of severity or vital organ dysfunction [24]. Symptoms may include febrile illness,
headache, dizziness, abdominal pain, vomiting, nausea and loss of appetite. A paroxysm
cycle of relapsing chills and fever is characteristic of the disease. These are synchronized
to the life cycle of parasites in the asexual blood stages, which contribute to most
observed symptoms [25]. Rupture of red blood cells infected with schizonts leads to a
release of toxins and hemazoin that stimulate host immune system to secrete proinflammatory cytokines that elicit an inflammatory response. Anemia may develop as a
result to the loss of red blood cells. P. falciparum is responsible for malignant tertian
malaria, whereas P. vivax and P. ovale are responsible for benign tertian malaria. These
describe the cycle of fevers that occur every third day. P. malariae causes benign quartran
malaria and the cycles occur every fourth day.

Severe malaria
Severe malaria is primarily caused by P. falciparum infections and is more fatal
with a high mortality [26]. This is hypothesized to be due to rapid growth of parasites and
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cytoadherence which leads to blockage in the microvasculatures [27]. This result in vital
organ failure, including pulmonary edema and acute renal failure, cerebral malaria,
severe anemia, hyperparasitemia, jaundice as well as acidosis and hypoglycemia [28].
These become serious problems as they can develop fairly quickly within hours and death
within a few days without prompt and proper treatment. Cerebral malaria patients
experience coma after hypoglycemia and/or seizures [29]. Infected red blood cells
sequester in brain microvasculatures and cause endothelial damage [30]. This can cause
blockage which deprives the brain of oxygen (cerebral hypoxia). Placental malaria in
during pregnancy involves parasites adhering to placenta putting both mother and unborn
child at severe risk [31]. Less common is severe malaria from P. vivax which has resulted
in fatal cases attributed to increasing resistance in Papua, Indonesia [32]

Diagnosis
Diagnosis for malaria is not always straightforward as several of the typical
symptoms are non-specific to malaria and are common to other diseases. This overlap
can lead to delays in diagnosis which impacts prompt treatment resulting in death in many
regions. Some factors that may complicate or influence the efficacy and identification of
malaria include sequestering of infected red blood cells, different forms of the
Plasmodium spp., and recurrent infections [33]. Diagnostic tests and techniques exist to
confirm malaria infection with microscopy and malaria rapid diagnostic tests (RDT)
recommended by the World Health Organization (WHO). Giemsa staining of thick and
thin blood smears allows for identification of parasite life stage, quantification of
parasitemia as well as differentiating between Plasmodium species. RDTs look for
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antigens expressed by parasites in infected blood and may detect and distinguish
between multiple species [24]. RDTs tend to be quick and cost efficient and do not require
lab equipment and electricity. Immunofluorescence antibody testing exists which detect
species-specific antigens [34]. These can be time consuming and limits their practical use
in most cases of acute malaria due to the time needed for antibody development, which
may take up to two weeks. They are however very sensitive and specific [33]. More recent
molecular developments have paved the way for newer diagnostic methods with high
sensitivity and specificity. PCR-based diagnostic tests are sensitive enough to pick out
infections with low parasitemia as well as detect drug resistant strains [33]. PCR testing
is limited due to its high cost, trained technicians capable of running the test and complex
methods. Other techniques include mass spectrophotometry and microarrays, which are
not routinely used due to required resources and high cost in additional to equipment and
quality control not practical for regions of some endemic developing countries [33].

Global health impact
Risk of malaria is widespread as it continues to be a significant parasitic disease
across the world with half the world’s population (over 3 billion people) estimated to be at
risk of being infected [35]. The most recent WHO Malaria World Report reported that there
were 214 million cases of malaria in 2015 with 438,000 global deaths [36]. It is primarily
found in countries with warm temperate climate due to optimal growth conditions for the
mosquito vector. Developing countries with limited access to antimalarials and poor
control programs tend to be most affected. P. falciparum is primarily endemic to Africa
where most fatalities occur and has a lower prevalence in other continents. The majority
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of these deaths occur in young children under the age of 5 that are particularly vulnerable.
Pregnant women also are at high risk for infection [31].
P. vivax has a larger worldwide distribution as it is endemic in most malaria inflicted
countries, especially those in South America, Oceania, Asia and Horn of Africa [37].
Several factors can explain why P. vivax is more prevalent. While very similar, P. vivax
and P. falciparum have different biology that effects transmission as well as treatment. P.
vivax is not as widespread in Africa due to decreased presence of the Duffy binding
protein in the human population. Merozoites of this species require interaction with Duffy
blood group antigens, found on the surface of young erythrocytes, for invasion [38].
Diagnosis can be difficult in asymptomatic patients due to low parasitemia. Methods of
malaria control such as antimalarials and insecticide-treated bed nets which may have
high efficacy against P. falciparum, are not as successful with P. vivax [39].

Malaria control and preventative measures
Malaria is a disease that is preventable, treatable and curable. Prevention and
control is achieved through a combination of vector control, protective measures and
antimalarial treatment. Different regions will implement different policies based on local
transmission level, financial burden and social conditions [40]. Insecticide-treated bed
nets offer a high level of protection while sleeping by preventing mosquito to human
interaction by repelling and killing them. Indoor spraying of insecticides in residential
areas can also lead to lower transmission. Together any combination of these
interventions may help reduce the incidence of malaria infection. However this has been
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hampered due to insecticide resistance, antimalarial resistance and financial costs of
control programs.
A global effort to eradicate malaria came in 1955 with the Global Malaria
Eradication Program [41]. Vector control in the form of DDT was used as an insecticide
that targeted adult mosquitos and helped in eliminating malaria in Europe and North
America. It however failed in many countries and was eventually abandoned by 1969.
Currently, the WHO Global Malaria Program aims to control and eliminate malaria by
2030 by reducing malaria case incidence and mortality rates by 90% and eliminating the
disease in at least 35 countries [36].

Vaccines
Vaccines have historically been instrumental in accelerating eradication of many
diseases that were once endemic to the world. An effective vaccine would be ideal to
helping eliminating malaria; however there is currently no commercially available vaccine
for the disease due to the complexity of the life cycle and its genetic diversity [42].
Potential vaccine candidates aim at targeting key points in the parasite life cycle that could
disrupt transmission and/or kill the parasite. Pre-erythrocytic vaccines (PEV) aim to
reduce the likelihood of becoming infected. These target the liver stages and aim to
prevent sporozoites from developing into blood stage infections. The most advanced
candidate is RTS,S/AS01, recently completed Phase III clinical trials [43]. It was able to
help protect young children for at least three years after vaccination but efficacy wanes
over time [44]. Blood-stage vaccines (BSV) aim to block infection in the blood stages
where most pathogenesis originates. Leading BSV candidates involve merozoite proteins
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involved in attachment and invasion of erythrocytes [45]. The first malaria vaccine
candidate, SPf66, was comprised of sequences of peptides from merozoite and CSP
proteins. It was abandoned due to low efficacy in phase III trials [46]. Finally transmissionblocking vaccines (TBV) do not help an infected person but block transmission of the
parasite to the feeding mosquitos that go on to spread disease to an uninfected person
[47].

Antimalarial Drugs and Resistance
Antimalarials have been effective agents used to combat malaria with proper
diagnosis and treatment. Some drugs are used as prophylactics to prevent infection while
others are used for treatment to eliminate infection. In either case, drug resistance has
been an obstacle that challenges effectiveness of malaria control and longevity of drug
use. Resistance to conventional drugs such as chloroquine and sulfadoxine/
pyrimethamine (SP) in malaria endemic regions has rendered them ineffective in those
areas and is a concern for other antimalarials. Parasites are well adapted to develop
resistance and several mechanisms have been identified, including point mutations in key
genes. Monotherapy has typically resulted in selecting for resistant parasites so
combination therapies with complementary drugs is considered the recommended form
of treatment.
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Quinolines
Quinine
Quinine, extracted from the bark of cinchona trees, was the first drug discovered
to treat malaria back in the 1600s. It was the predominant antimalarial used until the
1920s when more effective drugs were synthesized [48]. Quinine is very effective against
schizonts in P. falciparum with additional activity against gametocytes in P. vivax and P.
malariae. WHO recommends quinine paired with the doxycycline or clindamycin for
second-line treatment of uncomplicated malaria [24]. Unlike many other drugs, quinine
resistance has been slow. Limited resistance tends to involve decreased sensitivity as
reported in South America and Asia [49, 50]

Chloroquine
Chloroquine (CQ) is a 4-aminoquinoline derivative of quinine that became one of
the most widely used antimalarial drug after towards the end of World War II in 1945.
Digestion of hemoglobin by blood stage parasites produces heme, a toxic by-product in
the digestive food vacuole. Normally this is detoxified by parasite enzymes but it is highly
theorized that CQ interferes with this process when it accumulates in the vacuole. The
quinolones had effectively controlled malaria until emergence of resistant parasites had
spread by the late 1960s [51]. CQ resistance was identified along the Thailand-Cambodia
border in Southeast Asia and Panama-Colombia border in South America in the late
1950s. This migrated to nearby countries and was widespread throughout Africa by the
1980s. One potential reason for this was the introduction of CQ into table salt which may
have accelerated the rate of resistance formation [52].
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CQ resistance has been identified in parasites with mutations in the pfmdr1
(Plasmodium falciparum multidrug resistance gene 1) gene and the pfcrt gene that
encodes the Plasmodium falciparum chloroquine resistant transporter (PfCRT) protein
[53, 54]. This protein is localized in the food vacuole and a Lys-to-Thr amino acid
substitution at residue 76 (K76T) results in CQ resistance. This mutation causes the
protein to shuttle CQ out of the vacuole where it is active. CQ is used as a prophylaxis
and for treatment of P. vivax, which resistant strains have only been reported in Indonesia
and Papua New Guinea [55, 56].

8-aminoquinolines: Primaquine and tafenoquine
Primaquine is the only FDA licensed drug that kills dormant P. vivax hypnozoites
in the liver. It is an 8-aminoquinoline that has strong gametocytocidal activity against
stage V P. falciparum gameotcytes that is effective at blocking transmission. Primaquine
metabolism is not fully understood but it is strongly believed to be linked to cytochrome
P450 2D6 (CYP2D6) activity which metabolizes it [57]. Those metabolites generate
reactive

oxygen

species

by

oxidizing

hemoglobin

[58].

Glucose-6-phosphate

dehydrogenase (G6PD) deficiency limits the use of primaquine in areas where this is
prevalent due to resulting severe hemolytic anemia in patients. Resistance to the drug is
defined as a failure to clear liver stage parasites since it is not used as a schizonticidal
drug in the blood stages [42]. Due to primaquine’s short half-life that requires daily
treatment, leading to poor compliance and evidence of resistance, tafenoquine, another
8-aminoquinoline, was created as an alternative antimalarial for radical cure of P. vivax
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malaria [59]. Its mechanism of action is not known but it has been shown to be more
effective than primaquine [60].

Piperaquine
Piperaquine was first used as prophylaxis and treatment of malaria after it was
synthesized in the 1960s but this declined following emergence of P. falciparum resistant
strains and development of more effective drugs in the 1980s [61]. It was reintroduced in
the 1990s as a partner drug to dihydroartemesinin (DHA) due to effective clinical efficacy
and little toxicity. Resistance has been associated with copy number variation on
chromosome 5 (X5r) and pfcrt [62]. A recent study has reported piperaquine-DHA
resistance in Cambodia which has been attributed to failure in both drugs to effectively
clear infection [63]

Mefloquine
Mefloquine was introduced as an antimalarial after resistance to chloroquine and
pyrimethamine spread. It has been available since the mid-80s and is effective at
preventing malaria caused by chloroquine-resistant P. falciparum (CRPF) [64]. It is a
quinolone methanol that localizes and accumulates in the food vacuole where it is believe
to interfere with hemoglobin digestion. It is effective against blood stage parasites but has
no activity against liver stages. Resistance developed within 6 years along the borders of
Thailand [65]. Increased copy number of pfdmr1 is a marker for in vivo and in vitro
mefloquine resistance. Increased susceptibility is conferred by single nucleotide
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polymorphisms in vitro, however this is not the case in vivo [65]. It is often paired with
artesunate due to its strong activity and long half-life [66].

Antifolates
Antifolate drugs were first discovered in the 1940s and have been used as
prophylaxis and treatment of malaria. These inhibit the pathway for folate metabolism in
Plasmodium which is essential for growth. Folate cofactors provide purines and
pyrimidines for DNA replication and are required for amino acid synthesis and catabolism
[67]. The enzyme dihydropteroate synthase (DHPS) constructs dihydropteroate from paminobenzoic acid (pABA) and L-glutamate moieties. Dihydrofolate reductase (DHFR)
then converts dihydrofolate into its reduced form, tetrahydrofolate [67]. Plasmodium can
either synthesize folate de novo or salvage it from host plasma. Antifolate antimalarial
drugs fall into two classes; DHPS inhibitors (class I) and DHFR inhibitors (class II). These
act to decrease methionine synthesis and lower thymidylate levels, arresting DNA
replication in the process [68]. They are especially effective on late trophozoites when
DNA synthesis is high [68].
The primary DHFR inhibitors that have made it to at least Phase I trials in humans
include proguanil, cycloguanil, chlorproguanil, pyrimethamine and WR99210, the most
potent one [69]. These have higher binding affinity for Plasmodium DHFR over human,
making them strong drug candidates. They have slower activity against blood stage
parasites compared to quinine but are used as a prophylaxis or in combination with faster
acting drugs. Pyrimethamine is often administered in combination with sulfalene or
sulfadoxine due to strong synergistic effects. DHPS inhibitors interfere with parasite de
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novo synthesis of folate [69]. Dapsone (a sulfone) and sulfadoxine represent DHPS
inhibitors. Alone, they tend to be toxic and have low efficacy but have considerable
synergy with DHFR inhibitors. Sulfadoxine/pyrimethamine (SP) are often administered
together and have replaced chloroquine in areas where resistance has been reported
[68]. In vitro pyrimethamine resistance is attributed to point mutations in the dhfr domain
of the dhfr-ts gene [70]. SP resistance has developed and is associated with treatment
failure across Africa, Asia and South America [71]. It is ineffective in many of these areas
but is used in combination with Artemisinin-based combination therapies (ACT) [24].

Atovaquone
Atovaquone is a naphthoquinone that is administered in combination with
proquanil as Malarone™ for treatment of uncomplicated malaria and prophylactically to
travelers of malaria endemic countries [72]. Atovaquone inhibits the Qo site of the bc1
complex of the mitochondrial electron transport chain (ETC) to disrupt activity of the
mitochondrion [73]. This has direct effects on pyrimidine biosynthesis as the
mitochondrion provides orotate for it via dihyrdoorotate dehydrogenase (DHODH).
Resistance is associated with a point mutation at position 268 on cytochrome b resulting
in strains that become far less susceptible to Malarone™ treatment [74, 75].

Antibiotics
Several antibiotics used to treat bacterial infections are effective against
Plasmodium, unsurprisingly due to shared biology acquired through the apicoplast, a
plastid-like organelle with cyanobacterial origins [76]. Activity tends to be slow but some
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classes nonetheless are used as antimalarial prophylaxis or in combination with faster
acting drugs.
Most antibiotics exhibit what is known as a delayed death phenotype [77].
Exposure in the first life cycle interferes with apicoplast replication so that daughter
parasites in the second life cycle fail to inherit the organelle. Without an intact apicoplast
present, all associated metabolism is disrupted and parasites fail to replicate and die
within 96 hours. Morphologically parasites appear normal in the first 48 hours but
unhealthy schizonts in the subsequent life cycle fail to produce merozoites and therefore
are unable to complete schizogony. The delayed death effect results in a parasite
clearance delay, which is why these are paired with fast-acting drugs. This phenotype is
observed in parasites exposed to macrolides such as azithromycin, lincosamides such as
clindamycin and tetracyclines such as doxycycline [78].
Tetracyclines are broad-spectrum protein synthesis inhibitors that bind to the 30S
subunit of ribosomes to block aminoacyl-tRNA attachment in bacteria. They are used as
slow-acting antimalarials that target the apicoplast. The most commonly used one is
doxycycline, synthesized in the early 1960s. It is used prophylactically by international
travelers to Africa, Southeast Asia and South America due to its long half-life [79]. It is
often recommended as a partner drug to quinine or artesunate in treatment of severe
malaria [24]. To date, no clinical resistance to doxycycline has been reported.

Fosmidomycin
Following discovery of the methylerythritol phosphate (MEP) pathway in
Plasmodium, several drug targets were pursued. Fosmidomycin (FOS) and its derivative,
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FR900098 were found to inhibit growth in multidrug-resistant P. falciparum strains [80]. It
inhibits an apicoplast target that does not result in delayed death but rapidly kills parasites
within the first life cycle. Fosmidomycin inhibits 1-deoxy-D-xylulose-5-phosphate
reductoisomerase (DXR) a key enzyme in the isoprenoid biosynthetic pathway. Clinical
efficacy of fosmidomycin monotherapy is limited and not ideal as patients in Thailand and
Gabon developed highly recrudescent infections [81]. Symptoms cleared rapidly and
microscopic detection of parasites dropped below threshold for detection but parasites
were not fully cleared. Fosmidomycin has been tested clinically in combination with
clindamycin or artesunate. Both combinations resulted in high cure rates but adverse
effects such as neutropenia and vomiting were of concern [82, 83].

Artemisinin
Artemisinin is derived from the Chinese herb, qinghao of Artemisia annua L. also
known as sweet wormwood. Evidence of its use in fever treatment, traces back to 340
C.E [84]. Following failure of many drugs due to resistance and efforts to eradicate
malaria, an initiative was created to look for new antimalarial compounds [51]. Activity
against Plasmodium was first discovered in 1971 by Youyou Tu and its active ingredient
was isolated and termed qinghaosu or artemisinin as it is currently referred to [51].
Artemisinin is recognized as the leading drug to treat malaria. Since 2005, ACTs are
recommended by WHO as the gold standard of treatment. These include fast acting
artemisinin derivatives paired with a slower acting partner drug [24].
Among the many artemisinin derivatives include arteether (AE), artemether (AM),
artesunate (AS), artelinic acid (AL) and dihydroartemesinin (DHA), all of which vary in
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solubility and efficacy, but maintain strong activity against P. falciparum [85]. These
derivatives also vary in how they are metabolized and administered. Unlike artemisinin,
most of these derivatives metabolize to DHA in human body and inactive metabolites.
DHA tends to be the most potent, being more stable and effective than aretemisinin [51].
Artemisinins are among the most potent drugs used to treat malaria with inhibitory
concentrations (IC50) in the nanomolar range. The length of time it takes for the derivatives
to hydrolyze to DHA tends to mediate their activity with AS taking about 10 minutes
compared to AM’s slower conversion.
DHA has a short half-life of about 45 minutes and its fast activity is attributed to its
short elimination time. ACTs pair artemisinin derivatives with less potent drugs that act
slowly as there are less parasites to clear following metabolism of the artemisinins. Most
parasites are eliminated by artemisinins and the partner drug kills off residual parasites.
This combination also helps reduce the risk of resistance development by decreasing the
chance of selection of resistant parasites. The partner drugs theoretically should be able
to eliminate parasites that may develop artemisinin resistance [86]. Common
combinations include AM + lumefantrine, AS + amodiaquine, AS + mefloquine, AS + SP
and DHA + piperaquine [24].

Mechanism of action
Artemisinin’s mechanism of action is not fully understood and remains a topic of
hot debate. Artemisinin is a sesquiterpene trioxane lactone, bearing an endoperoxide
bridge believed to be key to its activity. One theory proposes that artemisinin is selectively
activated by parasites through interaction with free iron which is in higher abundance in
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infected erythrocytes due to digestion of hemoglobin. Iron cleaves the bridge and release
free radicals that are toxic to parasites [87]. This targets nucleophilic groups of proteins
and lipids, disrupts heme detoxification and depolarizes membrane potential [88, 89].
Another theory suggests it acts through inhibition of PfATP6, a sarco/endoplasmic
reticulum membrane calcium ATP-ase (SERCA) enzyme [90].

Artemisinin resistance
Southeast Asia has been a hotbed for emergence of multi-drug resistant P.
falciparum parasites resistant to antimalarials including chloroquine, pyrimethamine,
mefloquine and quinine [86]. ACT failure and resistance to artemisinin is emerging and
alarming. Artemisinin (partial) resistance is delayed parasite clearance following therapy
[91]. Full resistance is represented by strains that survive and multiply despite exposure
to drug doses equal or higher than what is recommended but tolerable to the subject [24].
Artemisinin full resistance has not yet emerged but partial resistance may select for
resistance in partner drugs. Point mutations in the PF3D7_1343700 kelch propeller
domain on chromosome 13 (K13) have been identified as a molecular marker for in vitro
and in vivo artemisinin resistance [92]. Kelch represents a superfamily of proteins that
contains protein-protein interaction sites and is involved in a variety of cellular functions
response to oxidative stress and protein degradation. K13 mutations in artemisinin
resistant parasites are less susceptible to incoming oxidative damage created by
artemisinins [86]. A recent study reveals phosphatidylinositol-3-kinase (PfPI3K), a binding
protein for K13, as a potential target of the drug [93]. K13 targets PfP13K for degradation
in sensitive parasites. Binding is disrupted in resistant parasites resulting in higher basal
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levels of PfP13K and P13-phoshphate (P13P) which enhances survivability of artemisinin
exposed parasites [94].

Dormancy
Dormancy in Plasmodium falciparum
Recrudescent infections are often observed when antimalarials are administered
alone. This is seen with artemisinin derivatives where recrudesce occurs in up to 50% of
patients that are given artemisinin monotherapy [95]. Length of treatment can reduce the
rate of recrudescence. Recovery from malaria occurs when parasite clearance is
observed in peripheral blood smears but this may not happen in highly resistant parasites.
Some resistant parasites may fall below the level of microscopic detection and lead to
recrudescence when parasitemia increases and clinical symptoms of malaria manifest
[96].
Dormancy as a concept has been theorized as a means by which P. falciparum
evades drug stress and eventually recrudescence following exposure to antimalarials. In
1996, Kyle and Webster reported a growth arrest of ring stage parasites exposed to AS
or DHA [97]. These “dormant” parasites resumed growth after 3-8 days. Ring stage
parasites are susceptible to stress which halts progression to the more mature trophozoite
stage. In vitro studies reveal that a morphological change is induced transforming the ring
into a small pyknotic like form identifiable by a condensed nuclei and cytoplasm and
absence of the vacuole. Exposure to 700 nM DHA for 6 hours is enough to induce this
phenotype in standard lab strains. This concentration and exposure length is
representative of serum level of DHA that is metabolized by patients treated with
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artemisinin derivatives. Growth commences when drug pressure is removed and the
erythrocytic cycle is able to continue development [98, 99]. Recovery ranges from 0.044%
to 1.313% following removal in a dose dependent manner. Recovery can also be reduced
with additional treatments of DHA over 3 consecutive days [99].
Dormant parasites are not completely quiescent as low levels of metabolism are
maintained. DHA was used to induce dormancy in P. falciparum and transcriptional data
of 12 genes encoding key enzymes in different metabolic pathways was assessed [100].
Most of these genes were downregulated but genes encoding pyruvate kinase 2 (pykii),
long-chain fatty acid elongation enzyme (lcfaee) and cytochrome c oxidase subunit II
(coxii) were maintained in the 48 hours following DHA treatment. The first two are
apicoplast proteins and the latter is of mitochondrion origin. Further analysis of apicoplast
genes during dormancy reveal that genes encoding enzymes used for pyruvate
metabolism, fatty acid synthase II (FASII) and lipoyl metabolism in the apicoplast are also
maintained.
Assessment of mitochondrial membrane potential with rhodamine 123 (RH)
reveals that a subset of artemisinin-induced dormant parasites RH-positive recover
whereas RH-negative parasites do not. Transcription of mitochondrial enzymes is only
present in RH-positive dormant parasites suggesting a critical role that mitochondria plays
in recovery from dormancy [101].
Hott et al demonstrated that pyrimethamine is capable of inducing a second cycle
ring-stage dormancy [102]. Rings of artemisinin-resistant and susceptible clones exposed
to the drug are not immediately arrested. Instead development continues through
schizogony and daughter rings in the subsequent life cycle are met with arrested growth.

21

Morphologically these parasites appear similar to those exposed to DHA and
recrudescence is observed 5-11 days later. In vitro recrudescence to atovaqone,
proguanil, mefloquine and pyrimethamine have also previously been reported in P.
falciparum [103-105].

Dormancy in other Plasmodium spp.
P. vivax is capable of developing into dormant forms known as hypnozoites upon
invading hepatic cells [106]. These hypnozoites can lead to relapse infection when they
resume growth. Relapse is also observed in P. ovale as well as the simian parasite, P.
cynomolgi but is not present with P. falciparum infections. Latency, described as the
period between initial infection and relapse can be anywhere from a few weeks to years
[107]. Long-latency P. vivax infections occur when primary infection or first relapse is
observed within months of initial mosquito bite. Short-latency infections appear more
rapidly with relapse rates up to 90% within 6 weeks of primary infection [37]. Relapse
infections in patients in non-endemic areas provide evidence of the presence of dormant
parasites that reside from previous infections. Mechanisms behind hypnozoite formation
and subsequent relapse remain unknown although there is a theory that interaction with
Anopheles protein following a bite from uninfected vector might activate these dormant
forms [108].
In vivo assessment of dormancy has been worked on using rodent models.
Synchronous P. vinckei petteri and P. v. vinckei infected with artesunate exhibited
dormant parasites 24 hours after treatment. Micrograph images revealed parasites that
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looked similar to P. falciparum [109]. This demonstrates that dormancy can be induced
in vivo and is not limited to in vitro parasite cultures.

Dormancy in Plants
Dormancy represents an important physiological mechanism in early plant
development that promotes survival and viability. There are several classifications of
dormancy in plants and each represents a developmental arrest that halts germination
[110]. Germination is a natural developmental process of a viable seed into a mature
plant. It starts with absorption of water by the seed resulting in embryo expansion.
Germination ends when the outer seed layers rupture, revealing the radicle, the growing
plant embryo. The definition varies but generally seed dormancy represents a mechanism
that prevents a

viable seed from germinating [111]. Primary dormancy describes

germination arrest in mature seeds; the seed is released from a plant already dormant.
This differs from secondary dormancy which describes mature seeds that undergo
dormancy following environmental cues. Seed dormancy is further subdivided into
embryo and coat dormancy. Abscisic acid, gibberellins, ethylene, brassinosteroids, and
auxins, cytokinins, all interplay to regulate dormancy and affect plant development [112].
The extent to which hormones and environmental cues dictate dormancy varies with
species [113]. Most research has been done with Arabidopsis thaliana, a model flowering
plant that has provided much knowledge on this phenomena, which is not fully understood
[114].
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Abscisic Acid
Abscisic acid (ABA) was originally thought to be involved in abscission,

the

detachment of plant parts such as leaf and fruit [115]. ABA is rapidly synthesized under
unfavorable conditions that induce stress, which include heat, salinity, chilling and
herbicide toxicity [116]. It serves as a positive regular of dormancy and negative regulator
of germination in many plant species. ABA binds to pyrabactin resistance I (PYR1)
receptors and PYR1-like (PYL) receptors which do not appear to be in other organisms
[117, 118]. Seed development corresponds to two peaks of ABA accumulation [119].
Maternal ABA is first produced by parent plant is transferred to seeds. This is unable to
induce dormancy, but it promotes embryo growth during embryo development and
increases seed yield [120]. The embryo provides the second peak and it is this ABA that
regulates dormancy.

Gibberellic acid
Gibberellins are diterpene phytohormones that function as growth promoters and
affect developmental processes. They compose of a class of gibberellic acids (GA), many
of which are nonbioactive [121]. The primary bioactive gibberellins are GA1, GA3, GA4
and GA7. They are negative regulators of dormancy and positive regulators of germination
that work antagonistically with ABA. GA-mediated dormancy releasing mechanisms are
unknown but it theorized to be possibly be due to secretion of hydrolytic enzymes that
weaken the outer seed testa [122].
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Dormancy and persistence in other organisms
Persistence has been described in organisms that exhibit a phenotype
representing dormancy. Tumor cells in cancer may go dormant following treatment.
Tumor dormancy is defined as a phase without cancer progression, in which a single
tumor cell or clusters show no signs of growth but have the capacity for malignant
progression [123]. This is responsible for relapses with a subset of cells that may survive
following initial treatment. Dormant cells ensure proliferation and may be more drug
resistant. Therapies not only select for cancer stem cells but rather those with resistance
mutations that make them less susceptible to forms of therapy [124, 125].
Some bacterial cells are able to evade antibiotic toxicity in the absence of genetic
change [126]. These drug-tolerant bacterial persisters originally make up a small
proportion of a population but grow exponentially and may be the cause of chronic
infections. While not entirely dormant, these cells undergo a growth arrest followed by
rapid expansion similar to dormancy and recrudescence that promotes survival of
antibiotic resistant bacteria. They are less susceptible to antibiotics due to the decrease
in cellular activity [127]. Persistence genes exist which provide genetic basis for this [128].
These were identified in mutant E. coli strains. The global regulators were associated with
increased tolerance to antibiotics and overexpression contributes to dormancy.

Apicoplast
Origins
The apicoplast is a relict plastid-like organelle common to most Apicomplexan
parasites but is absent in Cryptosporidium spp. and some gregarines [129, 130]. The first
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hints of this came from circular extrachromosomal DNA in Plasmodium lophurae, which
was initially thought to be of mitochondrial origin [131]. Discovery of the linear 6kb
mitochondrial genome disproved this and eventually it was determined that it was more
linked to plant and algal plastids [132, 133]. The complete genome of the organelle was
mapped in 1996 and found to highly resemble algal plastid DNA [134]. This circular
genome consisting of 35 kb is called the plastome [76, 135]. This number is reduced down
from 150 kb found in the average chloroplast due to highly selective pressure. It is about
86% A/T rich and contains 68 genes that encode less than 50 proteins, most of which are
nuclear encoded and targeted to other organelles [135-137].
The Apicomplexan plastid became known as the apicoplast and parasites today
evolved to contain it through two endosymbiotic events. Initially an ancient
cyanobacterium was engulfed by a heterotrophic eukaryote. This new red algae organism
was then engulfed by another eukaryote and with lateral genetic transfer evolved into
chromalveolates, which include dinoflagellates, diatoms and Apicomplexans via
secondary endosymbiosis. Evidence of this is seen in the apicoplast’s four membranes
and genome which is similar to that of red algae [136]. The inner membrane is the plasma
membrane of the endosymbiont and the next two originated from the red algal plastid.
The outer membrane originates from the host’s endomembrane [138]. Integrating the
endosymbiont into the host cell as an organelle involved using its resources, regulating
division and preventing it from escaping the host [138].
The plastid is no longer photosynthetic, having lost this ability as it is not needed
within a host. It is however essential for survival as disruption leads to parasite death
[139]. It is capable of four functions: heme biosynthesis, iron-sulfur cluster biosynthesis,
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fatty acid and isoprenoid biosynthesis. Genes for fatty acid biosynthesis were identified
in Toxoplasma gondii and P. falciparum in 1998 [140]. Shortly after a biosynthetic
pathway for isoprenoids was linked to the apicoplast [141]. Eventually it was elucidated
that the apicoplast produced iron-sulfur clusters and was involved in heme biosynthesis
[142].

Fatty Acids
Fatty acids are found in all living cells and are the building blocks of lipids, second
messenger precursors, energy storage molecules and are used for protein
posttranslational modification [143]. Fatty acids are synthesized by two distinct pathways.
Type I is generally found in fungi and mammals and Type II occurs in plants and bacteria
[144]. Type II fatty acid synthesis (FASII) pathway occurs in the apicoplast. Plasmodium
spp contains all enzymes required for FASII pathway and nuclear FASII genes encode
products that target the organelle [142]. Covalent attachment of acyl intermediates to acyl
carrier protein (ACP) is a feature unique to Type II. Addition of a 4’-phosphopantetheine
prosthetic group to the ACP is required for its participation in fatty acid biosynthesis [145].
ACPs transfer fatty acids between enzymes in the pathway and are localized to the
apicoplast [146].
A key product of FASII is lipoic acid, an essential co-factor of the glycine cleavage
system, pyruvate dehydrogenase (PDH), α-ketoglutarate dehydrogenase (KGDH) and
branched chain α-ketoacid dehydrogenase (BCDH). The latter three are multi-enzyme
complexes found in the mitochondria and apicoplast that contribute to amino acid and
energy metabolism [147]. Initially this pathway was an attractive target for blood stage
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drug discovery. We now know that FASII is nonessential in the blood stages as mutants
lacking this pathway remain viable, scavenging lipids from host. However deletion of key
FASII genes revealed that the pathway is essential in the liver stage as well as sporozoite
development in mosquito midguts [148, 149]. P. berghei lacking the LipB gene (which
encodes octanoyl-ACP transferase) develop normally in the blood and mosquito stages,
but this is disrupted in liver [150]. FabZ knockout in P. yoelli resulted in liver schizonts
that fail to produce merozoites [149]. Finally deleting P. falciparum fabI and fabB/F
resulted in midgut oocysts that did not produce sporozoites [148].

Iron-sulfur clusters
Iron-sulfur (FeS) clusters are protein cofactors that are involved in electron
transfer, sulfur atom donation, sensing process as well as structural roles [151]. They
consist of Fe2+/3+ and S2- ions [143]. FeS synthesis uses two pathways; the Isc pathway
localized in the mitochondrion and the Suf pathway found in the apicoplast, similar to
organization in plant plastids. The Suf pathway provides FeS clusters for lipoate
synthesis, redox and tRNA modification in the apicoplast. FeS clusters also serve as
cofactors for enzymes (IspG and IspH) in the final steps of the MEP pathway for
isoprenoid biosynthesis. The Suf pathway is required for apicoplast maintenance as SufC
dominant negative mutants do not contain the organelle [152].

Heme biosynthesis
Heme is a source of iron that can be used by FeS proteins [153]. Mammalian heme
is synthesized in the mitochondrion and primarily in plastids for plants [143]. The pathway
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for heme biosynthesis in Plasmodium however is a coordinated effort between the
apicoplast, mitochondria and cytosol. Synthesis begins in the mitochondrion where the
first and last two enzymes are localized. The rest are located in apicoplast and cytosol
and are shuttled by parasite transporters. De novo synthesis of heme is nonessential in
blood stages as there is an abundance of heme in host cell. It is however essential in the
mosquito and liver stages. Knockout of δ-aminolevulinate synthase (ALAS) and
ferrochelatase (FC), the first and last enzyme of the heme biosynthetic pathway resulted
in P. berghei parasites with reduced oocysts that failed to produce sporozoites [154].

Isoprenoids
The primary isoprenoid is the 5 carbon isopentyl pyrophosphate (IPP) and its
isomeric form dimethylallyl pyrophosphate (DMAPP). IPP is non-allylic and differs in the
position of its double bond. Multiple isoprene units (IPP or DMAPP) build on each other
to form longer isoprenoids such as the 10 carbon, geranyl pyrophosphate (GPP), 15
carbon farnesyl pyrophosphate (FPP) and 20 carbon geranylgeranyl pyrophosphate
(GGPP). This pathway is essential in the blood stages of Plasmodium as inhibition with
fosmidomycin leads to death but can be recovered with exogenous IPP [155]. Treatment
with antibiotics disrupts apicoplast development such that parasites in the second life
cycle fail to inherit one, resulting in death. This can also be rescued with exogenous IPP
(Figure 1.2).
The biological significance of isoprenoids cannot be understated as they represent
one of the largest class of metabolites found in all organisms, comprising of over 35,000
compounds [156]. They are utilized for a variety of cellular process including

29

mitochondrial ubiquinone cofactor (coenzyme Q) biosynthesis, protein posttranslational
modification, cell signaling, and tRNA modification [143]. Ubiquinones represent a major
end product of isoprenoid biosynthesis that play an essential role in mitochondrial electron
transport.

Most

surface

proteins

depend

on

dolichol

transfer

of

glycosylphosphatidylinositol (GPI) anchors to bind to membranes. Isoprenoids are also
required for protein prenylation which involves the attachment of either farnesyl or
geranylgeranyl to proteins. Additionally isoprene units are components of the long
chained carotenoids.

Carotenoids
Carotenoids are pigments produced by photosynthetic plants as well as some nonphotosynthetic bacteria and fungi [157]. These 40 carbon molecules share GGPP as a
precursor and are synthesized in plastids. They are known for their chemical and physical
properties used in scavenging freed radicals, light absorption and antioxidant activity.
Evidence of carotenoid biosynthesis was discovered in P. falciparum in 2009, utilizing [13

H] GGPP as a metabolic precursor to follow the pathway [158]. Phytoene, β-carotene

and lutein were all identified and characterized through high performance liquid
chromatography (HPLC) and mass spectroscopy. Norflurazon, an inhibitor of phytoene
desaturase, depleted downstream products while increasing phytoene levels. Additionally
an enzyme (PfB0130w) with phytoene synthase activity was identified. This catalyzes the
reaction that converts two molecules of GGPP into phytoene.
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Isoprenoid Biosynthesis
IPP is synthesized via two mechanisms in nature that vary in precursors and cell
localization (Figure 1.3). Most eukaryotes, including humans and plants, fungi,
archaebacteria and a few eubacteria utilize the classical mevalonate (MVA) pathway
[156]. This is also known as 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) pathway and
occurs in the cytosol. It begins with condensation of two molecules of acetyl-COA to
produce acetoacetyl-CoA. HMG-COA synthase converts this to produce HMG-CoA and
HMG reductase catalyzes the reaction to yield mevalonate. The next few steps differ
between eukaryotic and archaea organisms but the end result is one molecule of IPP.
Isoprenoid production is in high abundance in human hepatocytes using the MVA
pathway, but absent in erythrocytes [159].
It was originally thought that isoprenoids were only synthesized via the MVA
pathway but we now know it can occur in other organisms under a different system. Most
eubacteria, and plastid bearing organisms, such as Apicomplexans and plants, use the
2C-methyl-D-erythritol-4-phosphate (MEP) pathway [160]. This is also known as the 1deoxy-D-xylulose-5-phosphate (DOXP) or non-mevalonate pathway for isoprenoid
biosynthesis. Biosynthesis of isoprenoids via the MEP pathway is localized in the plastid
and eight reactions catalyzed by nine enzymes eventually yield IPP (Figure 1.3) [156].
Condensation of pyruvate and glyceraldehyde 3-phosphate (G3P) produces DOXP in the
first step catalyzed by DOXP synthase (DXS). The second step involves conversion of
DOXP to MEP by DXR. It is this process that is inhibited by fosmidomycin and grants it
its antimalarial activity. MEP cytidylyltransferase (IspD) then releases the pyrophosphate
from MEP in a reaction with CTP to produce 4-diphosphocytidyl-2-C-methylerythritol
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(CDP-ME) in the third step. CDP-ME kinase (IspE) uses ATP to phosphorylate CDP-ME
into CDP-MEP and ADP. MEcPP synthase (IspF) catalyzes the reaction that converts this
into MECP. IspG and HMB-PP reductase (IspH) both contain iron-sulfur clusters and
catalyze the reactions for steps 6 and 7. IspG converts MECP into 2-methyl-2-(E)-butenyl
diphosphate and IspH converts it into IPP. IPP isomerase (IspI) will isomerize the double
bond to form DMAPP. All enzymes are nuclear encoded and transported to the
apicoplast.
Evidence of isoprenoid biosynthesis in Plasmodium was reported prior to the
discovery of the MEP pathway. Ubiquinone-8 and ubiquinone-9 were both found in blood
of duck and monkeys infected with P. lophurae and P. knowlesi respectively in the late
1960s [161]. It would take three decades for the pathway to be confirmed as a metabolic
pathway in Apicomplexans [80]. The fact that it is not present in humans has made it an
attractive target for drug discovery [80, 162].

Abscisic acid in living organisms
Toxoplasma gondii
ABA was discovered to be produced by T. gondii which uses it for communication.
Nagamune et al. established that the plant hormone induces production of cyclic ADP
ribose (cADPR), a secondary messenger that stimulates calcium release [163]. ABA
supplementation promotes microneme protein 2 (MIC2) secretion in a dose dependent
manner as a result of increased calcium levels. Micronemes are required for cell invasion
and parasite motility. ABA is also mediates egress. ABA was not only detected and
quantified in parasites extracts through gas chromatography mass spectroscopy and
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ELISA, but was reduced in parasites exposed to 50 µM fluridone, an inhibitor of ABA with
antagonist roles in plants. FLD also prevents egress and promotes formation of
bradyozoites, the dormant cyst forms.

Humans
Human granulocytes produce ABA, which also stimulates calcium release via
cADPR [164]. Granulocytes are white blood cells of the immune system that respond to
external stimuli that cause inflammation or infection. They mediate phagocytosis of
foreign pathogens by producing reactive oxygen species (ROS) and nitric oxide (NO).
Supplementation with external ABA was shown to stimulate this. ABA also increases
insulin secretion from pancreatic islets and is stimulated by glucose concentrations [165].

Plants
ABA has expanded roles in plant organisms beyond dormancy regulation. It also
involved in calcium signaling by inducing intracellular calcium release via cADPR. This
occurs through its activation of ADP-ribosyl cyclase via a protein kinase A mediated
phosphorylation [166]. ABA has also been shown to be involved in oxidative stress
response. Levels of it can cause an increase in active oxygen species which in turn
induces expression of antioxidant genes and enhances activities of associated enzymes
such as superoxide dismutase, catalase, glutathione reductase [167]. ABA treatment to
A. annua plants also increases artemisinin content by increasing expression of genes in
the artemisinin biosynthetic pathway in a dose dependent manner [168]. Artemisinin was
found to be 65% higher in plants exposed to 10 µM compared to controls. Gene analysis
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shows a significant increase in expression of 3-hydroxy-3-methylglutaryl coenzyme A
reductase (HMGR), farnesyl pyrophosphate synthase (FPS), amorpha-4,11-diene
synthase (ADS), amorpha-4,11- diene C-12 oxidase (CYP71AV1) and cytochrome P450
reductase gene (CPR), all of which are genes involved in biosynthesis of artemisinin. As
a stress hormone it also mediates stromatal closure during drought and it has also been
shown to alter mRNA translation to regulate gene expression [169, 170].

Other organisms
ABA synthesis in some other organisms differs from the pathway found in plants.
Fungi utilize the mevalonate pathway to make IPP and as such the precursors in ABA
biosynthesis are not the same. ABA is created directly from farnesyl pyrophosphate (FPP)
that bypasses the long chained carotenoids [171]. ABA is also found in cyanobacteria
and production is increased under conditions that induce salt stress [172] ABA role as a
global mediator of Ca2+ release is conserved across several species. It is found in the
sponge species, Axinella polypoides [173]. Heat stress, similar to drought stress in plants,
results in increased levels of ABA which in turn stimulated cyclase activity. ABA is
involved in a signaling cascade in the hydroid, Eudendrium racemosum [174].
Endogenous ABA stimulates cADPR activity resulting in an increase of Ca2+ during light
mediated regeneration and could be inhibited with fluridone. Exogenous ABA is able to
stimulate cyclase activity during the dark. Exogenous ABA also enhances growth of green
alga, Chlamydomonas reinhardtii, as well as induces tolerance to oxidative stress through
enhancement of antioxidant enzyme activity [175].
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Scope of study
Malaria, the infectious disease caused by Plasmodium spp. remains a major
problem worldwide due in part to challenges faced such as increasing drug resistance
and parasite recrudescence following treatment. This may be partially explained by
dormancy, a mechanism that allows the parasite to escape stress such as that induced
by current antimalarial treatments. Drug-induced dormancy involves the parasite entering
a state of low metabolic activity, where infection may appear to have been cleared, but
recrudescence occurs when parasites resume normal growth. Currently, the molecular
basis for how the parasite is able to regulate dormancy and recrudescence is not well
understood. We believe that ABA, a carotenoid catabolite with a well-established role in
seed dormancy in plants, may answer some of these questions.
Isoprenoid synthesis in Plasmodium requires the apicoplast, an organelle that was
originally obtained via a secondary endosymbiotic relationship with red algae. The
primary isoprenoid is IPP, which is essential for a number of metabolic processes and
serves as the precursor for carotenoid biosynthesis and its catabolite, ABA. In this study,
we discovered the presence of ABA in the erythrocytic stages of P. falciparum using gas
chromatography mass spectroscopy to detect and quantify ABA levels in methylated
parasitic extracts exposed to fluridone, a carotenoid inhibitor of ABA, and apicoplasttargeting antibiotics. Our preliminary data detected ABA and found it to be significantly
decreased when exposed to these drugs. Following in vitro induction of dormancy with
DHA, parasites were observed to resume growth earlier when supplemented with ABA
and GA. We also found that FLD can extend the length of dormancy and cause a delay
in recrudescence.
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We hypothesize that exposure to the phytohormones, ABA and GA, would
stimulate recrudescence in DHA-induced dormancy in erythrocyte stages. We also
believe that P. falciparum can biosynthesize ABA de novo. In this study, we aimed to
characterize the biosynthetic pathway of ABA using an innovative approach with
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labeled precursors to follow incorporation into ABA and intermediates. We also aimed to
elucidate the role that ABA and GA have in drug induced dormancy using
dihydroartemesinin. Our research strategy, which involved taking a novel approach by
utilizing the evolutionary link between plants and parasites should help us broaden our
understanding of parasite drug evasion and have an impact on development of
antimalarials.
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Figure 1.1: Plasmodium Life Cycle. The Plasmodium life cycle begins when a feeding
female mosquito takes a blood meal and injects sporozoites from the salivary gland
through the skin where they pass through the blood stream and eventually reside in a
liver cell. During the exo-erothryocytic cycle, replication occurs and a hepatic schizont
develops with merozoites that will be released into the blood following rupture. The
erythtocytic cycle commences when a merozoites invades a red blood cell to form a ring
which matures into a trophozoite, followed by a schizont which releases merozoites when
the infected red blood cell bursts. The cycle is continued when a new invasion has
occurred. A subset of rings may develop into sexual male and female gameotcytes which
are ingested by feeding mosquitos. Within a mosquito midgut, male microgametes will
exglagellate and fertilize female macrogametes, forming ookinetes which develop into
oocysts. These release sporozoites upon rupture which make their way to the salivary
glands, ready to infect a new person.
© CDC; http://www.cdc.gov/dpdx/Malaria/
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Figure 1.2: Evolutionary dependence of IPP. Following a primary endosymbiotic event
with a cyanobacterium and ancient protist, a secondary endosymbiotic event occurred
when red algae was engulfed by a protist host. Mevalonate synthesis of IPP was
redundant and therefore lost, leaving IPP synthesis via the DOXP pathway retained in the
nonphotsynthetic apicoplast. IPP is shuttled outside the plastid to other parts of the
parasite that use it. FOS inhibits the pathway by targeting DXR in the plastid. Antibiotics
interfere with apicoplast replication, resulting a delayed death that can be chemically
rescued with exogenous IPP.
© Nair SC, Striepen B (2011) What Do Human Parasites Do with a Chloroplast
Anyway? PLoS Biol 9(8): e1001137. doi:10.1371/journal.pbio.1001137
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Abbreviation
CDP-ME
CDP-MEP
DMAPP
DOXP
DXR
DXS
G3P
HMBPP
HMG-CoA
IPP
IspD

Definition
4-diphosphocytidyl-2-Cmethylerythritol
CDP-ME phosphate
dimethylallyl pyrophosphate
1-Deoxy-D-xylulose 5-phosphate
DOXP reductoisomerase
DOXP synthase

Abbreviation
IspE

Definition
CDP-ME kinase

IspF
IspG
IspH
IspI
ME-cPP

glyceraldehyde 3-phosphate
(E)-4-Hydroxy-3-methyl-but-2-enyl
pyrophosphate
3-hydroxy-3-methy-glutaryl-CoA
isopentyl pyrophosphate
MEP cytidyltransferase

MEP
MVA

MecPP synthase
= HMB-PP synthase
HMB-PP reductase
IPP isomerase
methylerythritol
cyclodiphosphate
methylerythritol phosphate
mevalonate

MVP
MVPP

mevalonate-5-phosphate
mevalonate pyrophosphate

Figure 1.3. Isoprenoid biosynthesis. Isoprenoid biosynthesis can occur via the
mevalonate (MVA) or methylerithritol (MEP) pathway. Cell localization, precursors and
enzymes differ. Plasmodium contains only the MEP pathway and it is localized in the
apicoplast. It begins with a molecule of glyceraldehyde 3-phosphate (G3P) and pyruvate
to produce IPP and DMAPP.
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Chapter 2
Phytohormones stimulate early recovery in Plasmodium falciparum dormancy

Abstract
Several organisms undergo dormancy as a stress response to survive under
unfavorable conditions that might impede development. This is observed in seed and
buds of plants and has been proposed as mechanism of drug evasion and resistance
formation in Plasmodium falciparum. We explored the effects of the phytohormones,
abscisic acid and gibberellic acid, on dihydroartemesinin induced dormant P. falciparum
parasites in the erythrocytic stages. Parasites were phenotypically observed to emerge
from dormancy earlier when exposed to these hormones and this could be delayed in the
presence of fluridone, a carotenoid inhibitor. Additionally the role of the apicoplast was
assessed in dormant parasites. These parasites remain viable for up to 8 days without
the organelle and only recrudesce if supplemented with the isoprenoid, isopentyl
pyrophosphate (IPP). Isoprenoid inhibition with fosmidomycin did not prevent dormancy
release from occurring in parasites with an intact apicoplast, but IPP and geranylgeranyl
pyrophosphate (GGPP) are needed for complete recrudescence.

Introduction
About 214 million cases of malaria and 438,000 deaths were reported in the past
year [36]. Plasmodium falciparum is responsible for the most deadly form of the disease,
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contributing to most morbidity and mortality. Artemisinin-based combination therapy
(ACT) remains the World Health Organization’s recommended antimalarial treatment due
to the potent and fast activity of artemisinin (ART) and its derivatives to clear parasites.
Pairing these drugs with slower acting antimalarials increases the effectiveness of
treatment while reducing the risk of recrudescence and resistance that often follows
monotherapy. Despite global efforts to circumvent this, ART resistance is developing as
an emerging threat and has been a target of interest especially in the Southeast Asia
region of Thailand and Cambodia where it is spreading [176].
Dormancy is characterized by a stress induced growth arrest in the asexual ring
stages, and has been proposed as a mechanism for drug evasion and subsequent
recrudescence following removal of drug pressure [97]. Early development is arrested as
dormant forms take on morphology characterized by a condensed nuclei and reduced
cytoplasm. ART drugs have been demonstrated to induce this at high concentrations
(700nM) in vitro [99, 177]. In vitro recrudescence follows removal of drug as parasitemia
increases to detectable levels [98, 100]. Dormant parasites are not completely quiescent
as low levels of metabolic activity are maintained, especially in the case of fatty acid
synthesis and pyruvate metabolism [98, 100]. In vivo evidence of dormant parasites is
also supported following artesunate treatment to P. vinckei petteri and P. v. vinckei in a
rodent model [109]. Growth was arrested and micrographs revealed forms reminiscent of
dormant P. falciparum parasites. More recently the antifolate, pyrimethamine, has been
shown to induce a second cycle dormancy in daughter rings following exposure in the
previous life cycle [102].
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Growth arrest is not exclusive to Plasmodium as a related phenomenon is
observed in plants where dormancy has been previously described [178]. This can be
triggered by abiotic stress (drought, salinity, temperature) and results in an early
developmental arrest that confers protection from unfavorable conditions that might
otherwise disrupt seed or bud development and kill the young plant. This is regulated by
a network of signaling hormones that include abscisic acid (ABA) and gibberellic acid
(GA) that work antagonistically to promote and release dormancy [179, 180].
Apicomplexa organisms share a common ancestral origin with plants which may
account for similarities. This comes in the form of the apicoplast, a non-photosynthetic
organelle evolutionarily obtained following a secondary endosymbiotic relationship
between a eukaryote and red algae. This is evidenced by its four membranes and shared
metabolic pathways [153, 181]. The apicoplast’s sole essential function in the erythrocytic
stages is to synthesize isoprenoids [155]. This occurs via the non-mevalonate pathway
using pyruvate and glyceraldehyde 3-phosphate as starting materials and has been
conserved across plastids [80].
Dormancy may be a mechanism conserved and shared between Plasmodium and
plant organisms. In this study, we explored dormancy regulating phytohormones in in vitro
dormant parasites and observed an early recrudescence phenotype across several
strains of P. falciparum. We also show the importance of isoprenoids in the recovery of
dormant forms with and without an apicoplast. Together these findings help shed light on
a mechanism that is not fully understood.
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Materials and Methods
In vitro Plasmodium falciparum culture
Lab strains W2 (Indochina), 3D7 (Netherlands), D10-ACPLEADER-GFP (MRA-568),
and ARC08-88 (11G) (Cambodia patient isolate) [182] were maintained in culture using
previously described methods [12]. Cultures were maintained in complete medium
consisting of RPMI-1640, 0.5% Albumax II, 0.2% sodium bicarbonate, 50 mg/L
hypoxanthine, 25 mM HEPES and 2% O+ human red blood cells (RBCs; Interstate Blood
Bank, Memphis, TN). D10 was cultured in the presence of 100 nM pyrimethamine. For
dormancy experiments and drug assays, cultures were synchronized to ring stage using
5% (wt/vol) D-Sorbitol (Sigma-Aldrich) and washed three times with RPMI [183].

Dormancy induction
Dormancy was induced by adding 700 nM dihydroartemisin (DHA) to synchronized
rings. Parasitemia was adjusted to 2% in 4% hematocrit and parasites were exposed to
DHA for 6 hours except where noted. After DHA was washed out, 100 μM (±)-abscisic
acid (Acros Chemicals), 50 μM fluridone (Sigma-Aldrich), or 10 μM gibberellic acid
(Sigma-Aldrich) was added to culture. 1 mL of parasites were seeded in 12-well plates in
duplicates. A sham control with vehicle (DMSO) was also grown in parallel. Giemsastained thick and thin blood smears were obtained daily and used to monitor
recrudescence and growth. Complete media was changed every 48 hours. Experiments
were done with two replicates at least twice.
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Drug susceptibility assays
Drugs were serially diluted 1:2 in complete media in 96-well plates. 10 μL of drug
was transferred to a new plate with 90 uL/well of synchronized ring-stage parasites at
0.5% parasitemia and 2% hematocrit. After 48 hour incubation, 1 μCi of [3H] hypoxanthine
monochloride was added to each well and allowed to incorporate for an additional 24
hours. Plates were then frozen at -80 °C. For assays with artemisinin drugs, hypoxanthine
was added at time 0 and allowed to incubate for 48 hour prior to freezing [98]. Plates were
thawed, washed and harvested in a FilterMate cell harvester. 50 μL scintillation cocktail
was added to each well and plates were read in a TopCount NXT scintillation counter.
Data was imported into TriFox DataAspect Plate Manager software for calculation of 50%
inhibitory concentration (IC50) and curve fitting analysis.

Geranylgeranyl pyrophosphate (GGPP) rescue in isoprenoid-inhibited parasites
Ring-stage synchronized luciferin expressing 3D7 was exposed to 1-100 μM
fosmidomycin (FOS [Sigma-Aldrich]) to inhibit isoprenoid biosynthesis or pretreated with
2 μM doxycycline (DOX [Sigma-Aldrich]) for 48 hours to generate parasites without an
apicoplast [43]. Parasites were plated in 24-well plates at starting parasitemia of 0.5% in
2% hematocrit. 200 μΜ isopentyl pyrophosphate trisammonium salt (IPP [Isoprenoids,
LC]) or 0.02, 0.2, 2 or 20 μΜ geranylgeranyl pyrophosphate trisammonium salt (GGPP
[Isoprenoids, LC]) was added to each drug treatment. A control with vehicle (ethanol) was
also plated. Aliquots were taken daily and combined with 150 μg/mL D-luciferin (Perkin
Elmer) for 10 minutes prior to luminescence reading on a TopCount NXT scintillation
counter. In a separate experiment, 2 μM GGPP was given to parasites treated with 5 μM
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FOS. On day 4, GGPP was removed from one of these groups, while FOS was
maintained in culture. Micrograph images were obtained daily.

Isoprenoid inhibition in dormant parasites
Synchronous ring stage D10-ACPLEADER-GFP parasites were pre-treated with 2 μM
DOX for 48 hours and then sorbitol synchronized again. Parasitemia was adjusted to 2%
in 4% hematocrit. 700 nM DHA was used to induce dormancy and this was washed out
after 6 hours. 200 μΜ IPP, 2 μΜ GGPP, 100 μM ABA or 10 μM GA was added and
maintained in the presence of DOX. In a separate experiment, 5 μM FOS was used to
inhibit isoprenoid synthesis in dormant parasites. FOS was added at the same time as
DHA and maintained in culture. 200 μΜ IPP or 2 μΜ GGPP were added following DHA
removal and kept in media. Fluorescent images and slides were taken daily.

Fluorescence microscopy
For fluorescent images, D10-ACPLEADER-GFP parasites in 0.1% hematocrit were
incubated with 1 μg/mL Hoescht 33342 nuclear stain and 50 μM MitoTracker Red
CMXRos for 20 minutes at 37°C followed by 3 washes with RPMI.

Cells were

resuspended in complete media and allowed to settle onto 8 chambered slides (Thermo
Scientific) coated with 0.05 mg/mL poly-L-lysine. Images were obtained on a DeltaVision
CORE microscope (Applied Precision) using a 100x objective.
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Results
Abscisic acid and gibberellic acid stimulate early recrudescence in dormant
parasites
Plant dormancy is a response to external stress during an early developmental
stage regulated by endogenous hormones. Without confirmation that the same
metabolites exist in Plasmodium, we aimed to determine what effect exogenous
supplementation of phytohormones might have in influencing the response of parasites
by first inducing dormancy in the early ring stages and then exposing them to the
phytohormones. Initially 100 µM ABA was supplemented to DHA-induced dormant
parasites and maintained in culture media. Daily thick and thin blood smears were
collected and examined microscopically for parasites exhibiting normal morphology
(rings, trophozoites, schizonts) compared to dead and dormant forms. The ratio of normal
to total (normal + dead/dormant forms) was used to monitor recovery. Following DHA
exposure, all 3D7 parasites had become dead or dormant within 24 hours. Normal
parasite morphology was first observed by day 3 in cultures treated with ABA. This occurs
about 24 hours earlier than groups which had only been exposed to DHA. While initial
growth is first observed when exposed to ABA, parasites did not grow any faster (Figure
2.1A). The same effect is observed with W2 parasites (Figure 2.1B). If 50 µM fluridone
(FLD), an ABA inhibitor, is supplemented to parasites following dormancy induction and
removed on day 2, recovery is delayed by at least 2 days (Figure 2.1C).
We next explored the effects of gibberellic acid (GA). GA promotes germination of
the seed in plants and acts to release them from dormancy. One would expect it to act
antagonistically with ABA but when GA was supplemented in the same manner as ABA,
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we observed a similar response. GA-treated parasites showed initial signs of normal
morphology 48 hours earlier than DHA alone. This effect is achieved with 10 µM GA,
making it more potent and efficient at stimulating recovery than ABA (Figure 2.2).

Fluridone causes a delay in recrudescence of dormant parasites
Fluridone is an herbicide that binds to phytoene desaturase and inhibits carotenoid
and ABA biosynthesis [184]. It acts on seeds to reverse the effect of ABA and releases
them from dormancy. When dormant parasites are exposed to this for 2 days,
recrudescence is delayed and the antagonism with ABA is maintained. We aimed to
further explore FLD’s dormancy promoting effects through prolonged exposure to it.
Dormancy was induced with DHA and 50 µM FLD was added following the wash and
removed at varying time points (days 2, 8, 10, and 12). FLD prevents recovery as all
dormant parasites fail to recrudesce in its presence. If FLD is removed 2 to 8 days postdormancy induction, parasites start recrudescing 2 to 4 days later. After 8 days, removing
FLD does not have an effect as these parasites fail to recover and clear out of culture
(Figure 2.3).

An artemisinin resistant patient isolate displays an early recrudescence phenotype
when exposed to ABA and GA
ABA, GA and FLD all have an observable effect on DHA-induced dormancy of
standard lab strain parasites but can that be replicated in an artemisinin-resistant patient
isolate? To answer our question, we ran similar experiments with ARC08-88 (11G), a
clone from patient isolate ARC08-88, which carries the Kelch 13 (K13) mutation [182].
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Multiple point mutations in the propeller domains of the Kelch gene on chromosome 13
(PF3D7_1343700) are associated with a delayed parasite clearance phenotype and
serve as a molecular marker for the spread of artemisinin resistance [92]. Because of its
resistance compared to W2 (Table 1), parasites were given two doses of 700 nM DHA
(at time 0 and 24 H) over 48 hours. ABA, GA and FLD were then added and FLD was
washed out after 48 hours. All parasites had arrested growth by day 3. Signs of normal
morphology was detectable in culture by day 8 in the GA-treated group and day 9 in the
ABA-treated group (Figure 2.4). Those exposed to just DHA showed signs of recovery on
day 10. FLD-treated parasites once again exhibited a delay with recovery beginning on
day 14. The findings of this suggest that the effects of the phytohormones are
independent of artemisinin resistance.

The apicoplast is required for recrudescence
Isoprenoid biosynthesis in the blood stages of Plasmodium, is the apicoplast’s only
essential function and inhibiting this has a direct effect on parasite viability. We explored
the apicoplast’s role in recrudescence of dormant parasites to determine if it was required
for recovery. Exposure to antibiotics such as doxycycline (DOX) results in parasites that
are unable to replicate an apicoplast in the second life cycle and experience a delayed
death effect [43]. All apicoplast related metabolism is disrupted, including production of
essential isoprenoids. Fosmidomycin (FOS) inhibits isoprenoid biosynthesis and results
in death in the first life cycle. In either case, parasites can be rescued with 200 µM IPP
supplementation [155]. The IC50 value for FOS in 3D7 is 1.25 ± 0.05 µM [185]. We found
that growth is sustained in parasites 5 µM FOS in the presence of GGPP and they die
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when it is removed (Figure 2.5A, B). Additionally, treating parasites with 0.2 – 2.0 µM
GGPP can rescue up to 10 µM FOS (Figure 2.6A, B). There is observed toxicity at higher
concentrations of GGPP and lower concentrations are ineffective. Previous work has
shown that 20 µM of geranylgeraniol, the alcohol analog of GGPP, rescues at 10 µM FOS
[155]. GGPP supplementation is not sufficient enough to rescue DOX-treated parasites
as they are able to progress into the second life cycle but die by day 4 (Figure 2.7).
D10-ACPLEADER-GFP was used in the experiments because it has a GFP tagged
acyl carrier protein that localizes to the apicoplast [186]. This can be visualized in dormant
and recovering parasites for confirmation of apicoplast presence or absence. 48 hour pretreatment with DOX was used to generate ring-stage parasites without the organelle, and
these parasites were then exposed to DHA to induce dormancy. ABA, GA, IPP or GGPP
was then added. IPP was also added four days after inducing dormancy in a separate
group to assess the effect that delaying exposure to the isoprenoid might have. Parasites
without an apicoplast only recovered when exposed to IPP, while ABA and GA treated
parasites remained dormant (Figure 2.8A). For parasites which received IPP on day 4,
normal morphology became visible by day 7 (Figure 2.8B).

Fluorescent imaging

confirmed that the DOX-treated parasites lacked an intact apicoplast yet were still able to
recover in the presence of IPP (Figure 2.9). Mitotracker staining revealed weakly detected
signals in dormant parasites that were blurry and lacked distinct morphology like actively
growing parasites. GGPP also failed to cause recovery in DOX-treated dormant parasites
(Figure 2.10).
The previous results with IPP prompted us to explore if the addition of it is time
dependent. DOX treated parasites were given IPP at the start, days 4, 8 and 16 post-
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dormancy induction. Parasites supplemented with IPP up to day 8 eventually recovered
(Figure 2.11A). The length of time it takes for parasites to be visible is extended, showing
up 10 days later when IPP is added on day 8 compared to when its added on day 4. GFP
signal was lost in some parasites later in the experiment. This is possibly due to not
culturing with pyrimethamine, which D10 is resistant to due to the selectable marker of
the original insert, for the duration of the experiment (Figure 2.11B). If IPP is added on
day 16, recovery was not observed. By day 30, all dormant/dead forms had been cleared
from culture.

GGPP and IPP supplemented parasites fully recrudesce in FOS-treated parasites
We also wanted to investigate dormancy in parasites that had isoprenoid
biosynthesis inhibited but maintained an intact apicoplast. Initially 5 µM FOS, which
inhibits DOXP reductoisomerase of the isoprenoid biosynthetic pathway, was added at
the start and maintained in media for the duration of the experiment. DHA was used to
induce dormancy as previously described. These parasites were also supplemented with
either 200 µM IPP or 2 µM GGPP. All parasites exited dormancy but only fully
recrudesced in the presence of IPP or GGPP (Figure 2.12A). Parasites exposed to FOS
alone, failed to progress past initial asexual life cycle and were killed (Figure 2.12B).

Discussion
Exploring plant biology offers an alternative avenue to further understand a survival
mechanism shared amongst both organisms that may have been evolutionarily passed
down. Dormancy has long been established in plants as an early developmental process
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that ensures viability of a young seed or embryo. The growth arrest triggered by external
forces under unfavorable conditions confers protection against stress that might kill or
interfere with that development. This isn’t entirely unlike what is observed with other
organisms. The concept of dormancy within the blood stages of P. falciparum was first
reported after parasites resumed growth following drug removal (Kyle and Webster 1996).
Exposure to the ring stages with artemisinins have been able to induce this in vitro [98,
99]. The molecular mechanisms underlying how parasites enter and exit a state of
dormancy are far less defined than they are in plant organisms and thus represent a gap
in our understanding. Dormancy may be contributing to antimalarial drug resistance that
develops, so elucidating this is vital. The scope of this study involved utilizing what is
known about how regulatory hormones influence plant dormancy and correlating that to
P. falciparum dormancy in addition to further analyzing the importance of the apicoplast
on recovery. In this study we demonstrate that parasites are released from dormancy
earlier when exposed to ABA or GA. Furthermore the apicoplast and specifically the
isoprenoids it produces are essential for recovery in dormant parasites.
The strongest connection between parasites and higher plant organisms is the
apicoplast. This organelle establishes an evolutionary link between very different
organisms that nonetheless share biology. Several genes, proteins, mechanisms and
biological functions have remained and that is apparent when comparing homology of the
plastids [187]. The MEP and carotenoids pathways have both been conserved. Not all
functionality has though as photosynthesis has been lost as intracellular parasites do not
need it.
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The first phytohormone we looked at was ABA as it is the primary dormancy
regulator in plants. As a signaling hormone, ABA senses stress (e.g. onset of cold weather
during winter, water drought) and accumulates, inducing a dormant response to prevent
germination, an outgrowth of an embryo from the seed [188]. This occurs during
secondary dormancy after a seed has been released from the mother plant. Dormancy is
maintained as long as ABA levels are kept high. In this context it protects the seed from
conditions that would inhibit development and/or kill it. Interestingly enough ABA does not
work in the same way with P. falciparum. Supplementing dormant parasites with it
encourages recovery as opposed to maintaining dormancy. This was observed with
several dormant strains (W2, 3D7, D10-ACPLEADER) as microscopic signs of normal
morphology was seen 24 hours before control groups. An important question is why ABA
seems to function differently here. Difference in functionality may be attributed to
evolutionary adaptations to how ABA is utilized in a different organism more complex than
plants. Maternal ABA produced by the mother plant and transferred to the seed is unable
to induce dormancy but rather promotes embryo growth [189, 190]. It is ABA produced
by the seedling that induces dormancy. The effect we are observing may be analogous
to how seeds of some plants are influenced by exogenous ABA. We also have data
suggesting that ABA is produced in the blood stages of asynchronous P. falciparum
(Chapter 3). Confirmation of ABA biosynthesis in dormant parasites might help us discern
between any differences between endogenous versus exogenous ABA effects. Initially
we tested ABA in dormant parasites using nanomolar concentrations ranging from 1 nM
to 100 nM. No effect was observed at these levels (data not shown). An effect was
observed when 100 μM was used.
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For parasites to be able to utilize supplemented ABA, there must be able to have
a mechanism to reach the parasite which would be crossing two membranes, the host
erythrocyte and parasite itself. A human anion transporter, Band 3, is expressed on red
blood cells and ABA uses it for entry into the host [191]. G protein α subunit GPA1 has
been identified as a plasma membrane receptor for ABA in Arabidopsis and yeast [192].
These transporters have not been reported in Plasmodium and a search on PlasmoDB
did not reveal potential candidates. What if ay ABA specific receptors exist is unknown.
We don’t fully understand the mechanism behind how ABA was able to stimulate
dormancy release. Our knowledge of the role of abscisic acid in Plasmodium is limited
and the earliest clues were first reported in related Apicomplexan parasite, Toxoplasma
gondii. T. gondii has been a model organism used to study other Apicomplexans due to
its relative ease of genetic manipulation, short life cycle and availability of many cell
markers. Nagamune et al. detected endogenous ABA in parasite extracts and studied its
effects on development [163]. T. gondii exists in two forms within humans, tachyzoites
and bradyzoites. Bradyzoites are cyst forms that go dormant as a response to stress
induced by host immune reaction. These dormant forms are protected and unaffected by
most drugs, similar to dormant P. falciparum. Within T. gondii, supplementation with
exogenous ABA mediates calcium (Ca2+) release by inducing production of secondmessenger cyclic ADP ribose (cADPR) [163]. This leads to elevated levels of intracellular
Ca2+ that stimulates protein secretion required for development and egress. Ca2+ is
required for asexual Plasmodium growth and invasion of erythrocytes [193]. Transient
receptor potential (Trp) channel homologs and IP3 for Ca2+ release have been identified
in Plasmodium spp [194, 195]. Ca2+ mediated release by ABA could be a possible theory
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to explain its mechanism in P. falciparum but more work will need to be done to confirm
this.
Several studies have also reported the presence of ABA in other eukaryotic cells.
ABA’s connection to cADPR and Ca2+ appears to be conserved across many species and
consistent to an additional functionality it has in plants [166]. It’s also been implicated in
human granulocytes as a pro-inflammatory cytokine that stimulates cADPR and
subsequent increase in intracellular Ca2+ [164]. ABA has been found in low
concentrations in some mammalian cells. It is found in human plasma depending on diet
consumption and therefore there was initial concern that parasites might scavenge it from
host cells. To reduce this risk, experiments were cultured with Albumax, a synthetic
culture media supplement, as opposed to human plasma.
ABA is the primary dormancy inducer in plants, whereas GA is the primary
dormancy releaser. They have opposing roles as a decrease in ABA levels in seeds is
associated with an increase in GA which stimulates germination. In our experiments, GA
not only was able to stimulate early release from dormancy, it did so at 10 fold
concentration less than ABA at about 24 hours earlier (Figure 2.2). This result was
somewhat surprising because the two are antagonistic in plants. During seed
development, GA ends dormancy and promotes germination and growth [179, 196]. Very
little work has been published investigating gibberellins with Apicomplexans. GA, along
with other growth promoters, has been previously investigated for its effect on P.
falciparum parasites. The hormone was found to increase the parasite multiplication rate
resulting in higher parasitemia when supplemented to blood stage cultures [197]. This
role as a growth promoter might help explain why its effect on dormant parasites is more
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pronounced than ABA. Different gibberellin biosynthetic inhibitors (inabenfide and AMO1618) are effective at killing P. falciparum parasites by causing cells to swell and rupture
[198]. As a growth promoter, GA might be stimulating P. falciparum growth signals in
dormant parasites to release from the growth arrest induced during dormancy. In plants,
the hormone is theorized to activate enzymes that release dormancy [122]. Proteins
associated with recrudescence are unknown but phytohormone influence on expression
might help reveal upregulation in genes that are key to this process.
The results with FLD are not entirely unexpected. As an inhibitor, it has an
antagonistic effect with ABA. It was not surprising that it would have the opposite effect
from ABA by keeping parasites dormant with exposure, but releasing them upon removal.
FLD is an ABA inhibitor with antagonistic role in plants and T.gondii. While it releases
seeds from dormancy, it actually induces a dormant response in T.gondii. FLD induces
formation of dormant bradyzoite forms that encyst and grow slowly [163]. Addition of FLD
to our culture prevents them from recrudescing but this can be reversed if FLD is
removed. However, supplementing ABA to FLD-treated parasites was unable to reverse
this. We also explored the effect of constant FLD pressure on non-dormant cultures.
Progression through life cycle was slow and parasitemia remained low but dormant
parasites did not develop (Figure A1).
Resistant parasites lose their sensitivity to antimalarials and dormancy is theorized
to be a mechanism that helps promote this by selecting for parasites that have become
resistant. We aimed to explore whether the observed phythormone effects were unique
to sensitive strains or if they could be replicated with an artemisinin-resistant strain with
longer innate recovery. ARC08-88(11G), a clinically relevant artemisinin-clone of ARC08-
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88 from Cambodia was selected. Its resistance is conferred by presence of the K13
mutation and it exhibits a similar in vitro dormancy phenotype as other strains exposed to
DHA. There was no difference detected in how it responded to ABA or FLD exposure
when dormant. This suggests that the response is independent of artemisinin resistance.
48 hour FLD exposure resulted in parasites that emerged from dormancy on day 14,
which was four days later than the groups exposed to only DHA. This is prolonged from
W2 and 3D7, where FLD causes a two day delay in recrudescence.
Isoprenoids are a large class of molecules found in all living organisms. The
apicoplast is required for isoprenoid biosynthesis, and ABA and GA, the two primary
dormancy regulating hormones are derived from isoprenoids in plant species. In
Plasmodium, they serve as building blocks for many metabolites such as ubiquinone and
are vital for various cellular functions [158, 199, 200]. They are essential for parasite
survival in the blood stages, but this has not been examined in dormant forms for viability.
In this study, we aimed to explore how essential the apicoplast and isoprenoids were to
recovery of dormant parasites. The apicoplast is an interesting organelle that has served
as a target for antimalarial development because it is the site of isoprenoid biosynthesis.
We exploited the fact that IPP can compensate for isoprenoid inhibition in apicoplastdeficient parasites and those that had the biosynthetic pathway directly disrupted with
fosmidomycin [155]. We have observed that downstream product, 20-carbon GGPP, can
achieve the same effect at lower concentrations when exposed to up to 10 FOS. GGPP
is used for carotenoid formation, geranylgeranyl prenylation of proteins.
The first approach involved inducing dormancy in apicoplast-deficient parasites.
Our results show that the apicoplast is required for recrudescence. In the absence of the
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organelle, parasites fail to recover but this may be overcome with IPP supplementation.
ABA, GA, and GGPP alone do not appear to be sufficient enough to promote recovery
from dormancy without the apicoplast present. This result was surprising, because initially
we expected parasites exposed to ABA and GA to exit dormancy, but then die as neither
can compensate for isoprenoid absence. Apicoplast-deficient parasites can survive up to
3 days supplemented with GGPP before dying. However these parasites do not exit
dormancy in the presence of GGPP. This suggests that IPP plays a larger role in recovery
and isoprenoid products not derived specifically from GGPP are necessary to “awaken”
parasites and maintain growth. IPP is the basic precursor for all isoprenoid products and
a network of these may be needed to exit and survive. One possible explanation is
mitochondrion function. IPP is a precursor of ubiquinone, an essential metabolite of the
electron transport chain. Dormant parasites exhibited low mitochondrial membrane
potential when stained with Mitotracker. In a previous study, exposure to atovaquone, an
inhibitor of the QO site of cytochrome b, resulted in delayed recovery of dormant parasites
[101]. Low levels of pyruvate metabolism are maintained in dormant parasites [100].
Pyruvate serves as one of the starting material for IPP production so this may possibly
be ramped up in dormant parasites as they prepare to exit dormancy.
We also noted that dormant parasites can remain viable for up to 8 days without
the organelle as long as IPP is supplemented by day 8. This helped confirm that they
were not dead, but had their development arrested in a dormant state. Interestingly
dormant parasites also remained viable for 8 days while under FLD pressure. Removal
past that point resulted in parasites that did not recrudesce.

57

Our second approach to inhibiting isoprenoid biosynthesis in dormancy involved
using FOS to directly target DXR in the apicoplast, preventing the pathway from
completion. These parasites retained the organelle and with it present, recrudescence
followed DHA exposure. Merely inhibiting isoprenoid production does not prevent a
release from their dormant state. However IPP or GGPP was required for full recovery.
This is due to the toxic activity of FOS which parasites are protected from while dormant,
but become susceptible to as rings that re-emerge. At this stage, isoprenoids are needed
to reverse the drug’s effect. A higher percentage of trophozoites and schizonts were
observed to exit dormancy in the FOS only groups. The few rings that were observed
were likely parasites that had just emerged from dormancy and not newly invaded
parasites from these schizonts. 5 μM FOS may not be sufficient for a complete block of
isoprenoid inhibition and therefore there may be a small amount of IPP present in the
parasites before they go dormant which might be used to recover.
Recently ABA was used to investigate malaria disease severity and parasite
transmission in mosquito and mouse host using P. yoelii [201]. The authors saw a
reduction in blood parasitemia and gametocytemia following ABA supplementation as
well as reduced transmission to mosquitos. It was determined that this decrease was
likely due to ABA stimulating the host’s immune system after exploring in vitro effects with
P. falciparum. There was no direct effect on in vitro development of the parasite as
asexual growth nor were gametocyte formation altered. This is consistent with ABA
exposure we’ve done across several life cycles of 3D7 (Figure A2). This study sheds light
on the effect of the hormone on host systems, which ABA affects and in turn reduces
parasite burden. Combined with its effect on dormancy, ABA could work to stimulate
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recrudescence and reduce parasite burden by further stimulating the host’s immune
response to help clear those residual parasites.
The findings of this study could potential have larger implications on dormant forms
seen in different Plasmodium species. The hypnozoites of P. vivax in hepatocytes remain
elusive as the precise mechanism behind their formations and subsequent relapses are
not fully understood. Further work will need to be done to examine any effect that
phytohormones may have in regulating dormancy in the liver stages. If ABA and/or GA
are able to stimulate a release from dormancy, theoretically a drug with good liver stage
activity could be used to clear infection. This is important as the number of antimalarials
that are able to target and effectively treat hypnozoites is limited.
In summary, enhancing our knowledge of dormancy and how it contributes to drug
resistance and evasion of P. falciparum will be important moving forward. The precise
mechanism behind how ABA and GA influence dormant parasites is not fully understood
but they may help further shed light on this survival mechanism. The apicoplast and IPP
also play important roles that are key to recrudescing and surviving following dormancy
induction by DHA.
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Figure 2.1. Effect of ABA in DHA-induced dormant parasites. (A) Synchronized 3D7
parasites were exposed to DHA for 6 h to induce dormancy. Following 3 times wash with
RPMI, 100 µM ABA was added and maintained in culture. Recovery was monitored in
Giemsa-stained blood smears and ratio of normal to total (dormant/dead + normal)
parasites was recorded. ABA supplemented parasites recovered earlier than parasites
which were simply given DHA. (B) A similar pattern is observed with W2. When 50 µM
FLD is supplemented and removed on day 2, parasites begin to emerge from dormancy
2 days later. (C) Micrograph images reveal normal parasites in smears of ABA
supplemented parasites 24 h earlier than DHA only parasites and 48 h later in FLD
supplemented parasites. Bars represent ± SEM

60

Figure 2.2. GA exposure leads to dormant parasites to recrudesce early. Dormant
parasites supplemented with 10 µM GA exhibited earlier signs of recovery than when
supplemented with ABA. Bars represent ± SEM
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Figure 2.3. Effect of FLD in DHA-induced dormant parasites. (A) FLD was added to
dormant parasites and removed at different intervals. Dormancy is maintained in the
presence of FLD, but can be reversed upon its removal up to 8 days. Parasites exposed
to FLD longer than 8 days fail to recover. Bars represent ± SEM
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Figure 2.4. ABA, GA and FLD display similar patterns with ARC088-88 (11G).
Artemisinin resistant Cambodian patient isolate ARC08-88 (11G). DHA was added at T=0
and 24 h and parasites were under drug pressure for a total of 48 h. After washing, ABA,
GA and FLD were added with FLD being washed out after 48 additional hours. Dormant
parasites began to exit on day 10, but when exposed to GA and ABA, parasites started
to wake up on days 8 and 9, respectively. A delay with FLD is observed as normal
parasites emerge starting on day 14. Bars represent ± SEM
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Figure 2.5. GGPP rescue in FOS-treated parasites. (A) 2 µM GGPP rescues parasites
exposed to 5 µM FOS. Parasites exposed to FOS fail to produce merozoites and do not
complete the life cycle. This is reversed with GGPP. (B) When GGPP is removed, the
toxic effects of FOS take over and kill parasites. Values are normalized to an untreated
control. Bars represent ± SEM
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Figure 2.6. GGPP rescue over wider range of FOS. (A) Rescue was explored in
parasites exposed to a range of FOS and GGPP. Ring-stage forms matching control were
observed at 96 hours when 10 µM FOS-treated parasites were given 0.2 and 2.0 µM
GGPP. (B) Toxicity is observed with 20 µM GGPP. RLU = relative luminescence units;
Bars represent ± SEM
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Figure 2.7. GGPP is not as effective at rescuing in DOX-treated parasites. Parasites
were pre-treated with DOX for 48 hours to produce parasites without an apicoplast.
Different concentrations of GGPP as well as an IPP control were added simultaneous
with DOX treatment. GGPP parasites survive up to 3 days with as little as 0.2 µM GGPP
but die by day 4. Growth is sustained in the presence of IPP. Bars represent ± SEM
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Figure 2.8. Apicoplast-deficient dormant parasites only recover when
supplemented with IPP. (A) Parasites were pretreated with DOX 48 hours prior to DHA
exposure to generate daughter parasites which lacked an apicoplast. DOX was
maintained in culture and IPP, GA and ABA were added for the duration of the
experiment. IPP was also added 4 days later. Only when supplemented with IPP did those
parasites recover. (B) Micrograph images reveal dormant forms in DHA+DOX treated
groups with signs of recovery in groups supplemented with IPP. Recrudescence was
observed in fluorescent images. The lack of localization of GFP signal is due to absence
of an apicoplast for the acyl carrier protein to localize to. These parasites are still able to
exit dormancy and proliferate due to the presence of IPP. Bars represent ± SEM
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Day 4

Day 14

Figure 2.9. Apicoplast-deficient dormant parasites only recover when
supplemented with IPP. Recrudescence was observed in fluorescent images. The lack
of localization of GFP signal is due to absence of an apicoplast for the acyl carrier protein
to localize to. These parasites are still able to exit dormancy and proliferate due to the
presence of IPP.
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Figure 2.10. Apicoplast-deficient dormant parasites fail to recover when
supplemented with GGPP. In the absence of an apicoplast, 2 uM GGPP is not sufficient
enough for recovery from dormancy. Following DHA treatment, GGPP was added, but no
active parasites were observed in blood smears. Bars represent ± SEM
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Figure 2.11. Parasites recrudesce when IPP supplementation is delayed. (A) DOX
was maintained in dormant cultures and IPP was added either at the start, 4, 8 or 16 days
post dormancy induction. If parasites are supplemented with IPP after 8 days, signs of
normal parasites can be observed by day 19. Adding IPP 16 days later appears to be too
late as those parasites never recovered. (B) Fluorescent images of parasites with IPP
added on day 8 reveal growing parasites. Bars represent ± SEM
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Figure 2.12. Inhibiting isoprenoid biosynthesis does not prevent parasites from
exiting dormancy. Ring stage parasites were given DHA to induce dormancy as well as
FOS which inhibits all isoprenoid biosynthesis, while maintaining an apicoplast. 200 µM
IPP or 2 µM GGPP was then added. All parasites exited dormancy, however complete
recrudescence was only observed in FOS-treated parasites supplemented with IPP or
GGPP. Without either, the effects of FOS kill the parasites as they start to recover. Bars
represent ± SEM
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Table 2.1. Artemisinin derivatives
IC50 (±SD) ng/mL
Strain

Artelinic
acid

artesunate

dihydroartemisinin

artemisinin

ARC08-88 (11G)

86.5 (±48.5)

7.0 (±3.4)

2.0 (±0.38)

17.6 (±4.5)

W2

20.4 (±13.2)

3.9 (±3.5)

1.3 (±0.53)

6.9 (±1.16)
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Chapter 3
Characterization of abscisic acid biosynthesis in Plasmodium falciparum

Abstract
Abscisic acid (ABA) is a plant hormone found in many organisms that plays a role
in regulating dormancy, calcium signaling and responding to stress. Isoprenoid
precursors of ABA are synthesized in the apicoplast, an ancient plastid evolutionary
passed down from a secondary endosymbiotic relationship between cyanobacterium and
red algae. Several metabolic pathways are common to Apicomplexan parasites and
higher plant organisms including type II fatty acid synthesis and the methylerythritol
phosphate (MEP) pathway for isoprenoid biosynthesis. Among the many metabolites
derived from isoprenoid, are carotenoids, pigments with antioxidant properties.
Carotenoid biosynthesis derived from the 20-carbon isoprenoid, geranylgeranyl
pyrophosphate (GGPP), is found in Plasmodium falciparum, similar to its presence in
plants. Here we establish an approach to synthesize

13

C3-GGPP and use it to

metabolically label this pathway in order to identify and confirm abscisic acid biosynthesis
in the erythrocytic stages of P. falciparum.

Introduction
The Apicomplexan apicoplast is the site of isoprenoid biosynthesis and this
proceeds via the MEP pathway common to other plastid bearing organisms. Isoprenoids
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represent a large class of molecules found in all living organisms that are essential
components of thousands of secondary metabolites. Multiple chains of isopentyl
pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP) bind together to form
diverse compounds that are utilized for various functions. The 20-carbon geranylgeranyl
pyrophosphate (GGPP), consisting of four isoprene units, is produced by head to tail
condensation of IPP to an allylic primer such as DMAPP. This serves as an essential
precursor for biosynthesis of ubiquinones, dolichols, several terpenes and terpenoids,
including carotenoids, gibberellins and chlorophylls [202]. It is also used in the prenylation
of proteins when a geranylgeranyltransferase transfers geranylgeranyl groups to the Cterminus of proteins. This posttranslational modification grants proteins biological activity
that may have regulatory or structural functions in cell growth, differentiation, membrane
movement or vesicle transport [203].
Of special interest is IPP’s role as the basic precursor of carotenoid biosynthesis.
Carotenoids are lipophilic pigments with antioxidant activity that are involved in
scavenging free radicals and light absorption. Two molecules of GGPP condense to form
phytoene, a 40-carbon long chain terpenoid that serves as the backbone for all
carotenoids. Synthesis of this represents the first committed step in the pathway and is
catalyzed by phytoene synthase. Different carotenoids are formed through alterations of
the base structure and addition of oxygen groups [157]. 9-cis-violaxanthin and 9-cis
neoxanthoxin are shuttled out of the plastid into the cytosol where they are catabolized to
the 15-carbon xanthoxin. Rearrangement of this structure will yield the sesquiterpene,
abscisic acid (ABA). Evidence of carotenoid biosynthesis in P. falciparum was previously
reported using [1-3H] GGPP as a metabolic label [158]. Several carotenoids common to

74

plants such as phytoene, lutein, and β-carotene were also identified, in addition to an
enzyme (PfB0130w) with phytoene synthase activity. Treatment with norflurazon (NFZ),
a potent phytone desaturase (PDS) inhibitor in plants, led to an accumulation of phytoene
and reduced downstreams levels of carotenoids in parasites. ABA biosynthesis however
has not been confirmed (Figure 3.1).
ABA serves as a regulator of dormancy in plants as well as has additional functions
as a stress sensor and calcium agonist. We’ve shown that supplementing it to dormant
Plasmodium falciparum parasites results in stimulating early recovery from dormancy
(Chapter 2). To date the only evidence that ABA is found in Apicomplexan parasites
comes from work done on Toxoplasma gondii. ABA was detected in parasite extracts
using gas-chromatography mass spectroscopy and it plays a role in parasite development
and egress from host cell [163]. Fluridone (FLD), an herbicide inhibitor of carotenoid
biosynthesis, was found to reduce levels of ABA and stimulate formation of dormant cysts.
In this study, we hypothesized that the biosynthetic pathway to produce ABA has
been retained in Plasmodium. We aimed to confirm and characterize this in the blood
stages of P. falciparum using 13C3-GGPP to metabolically label the pathway. The novelty
of our approach comes from having a label on three of the isoprene units that make up
the molecule by first synthesizing
13

13

C-IPP, and then using a GGPP synthase to create

C3-GGPP from 13C-IPP and DMAPP. We show for the first time GGPP synthesized with

three

13

C labels in order to metabolically label the carotenoid pathway and confirm ABA

production.
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Materials and Methods
In vitro Plasmodium falciparum culture
Lab strains W2 and 3D7 were maintained in culture using previously described
methods [12]. Cultures were maintained in complete medium consisting of RPMI-1640,
0.5% Albumax II, 0.2% sodium bicarbonate, 50 mg/L hypoxanthine, 25 mM HEPES and
2% O+ human red blood cells (RBCs; Interstate Blood Bank, Memphis, TN) at 37 ºC

Gas-chromatography mass spectroscopy analysis of P. falciparum extracts
1 mL asynchronous 3D7 culture was incubated in 12-well plates at 2% parasitemia
in 4% hematocrit. 10 µM clindamycin (CLI), 5 µM chloramphenicol (CAM), and 5 µM
mirincamycin (MIR) were added to wells. Fluridone was added at concentration of 50 µM.
A control with 0.1% DMSO and untreated RBC samples were also prepared. This was
done in triplicate. After 24 hours, erythrocytes were lysed with 0.5% saponin and washed
three times with PBS at 4 ºC. Samples were then stored in -80 ºC prior to analysis.
A quantitative methylation of ABA was achieved through the dropwise addition of
an ethereal solution of freshly prepared diazomethane (70 mg, 1.66 mmol) to a stirred
solution of ABA (100 mg in 5 mL of ether) (Figure 3.2). The reaction was allowed to react
at ambient temperature for 30 min. The ether and excess diazomethane was removed
under nitrogen to afford white crystals.
Four stock solutions of methylated ABA at various concentrations, were prepared
to a final concentration of 0.09, 0.5, 0.7 and 1.1 µM. The auto-pipettes were calibrated
prior to use where both accuracy and precision were found to have an acceptable
deviation of -0.8% and 2.7% respectively. Injections of 0.1 - 5.0 µL were injected into the
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gas chromatographer using a HP-5ms column (30 m, i.d. 0.25 mm) incubated at an initial
oven temperature of 100 °C and heated to a final temperature of 300 °C at a rate of
30 °C.min-1. The elution of the methylated ABA was determined using selective ion
monitoring set to 278.3 ± 1.0 m/z. This molecular ion was formed through chemical
ionization using methane as the reactant gas which was administered at 2 mL.min-1. All
injections were conducted in triplicate and the mean and standard deviation calculated.

ABA detection in isoprenoid rescued parasites
3D7 was synchronized with 5% (wt/vol) D-Sorbitol (Sigma-Aldrich) and washed
three times with RPMI. 5 µM FOS or 2 µM DOX was added. For FOS-treated groups, 2
µM GGPP or 200 µM IPP were added at the start. After 24 hours, parasites were saponin
lysed and washed 3 times with PBS in 4 ºC, then stored in -80 ºC. For DOX-treated
groups, parasites were resynchronized after 48 hours and parasitemia was adjusted to
2%. DOX was added in addition to 2 µM GGPP or 200 µM IPP. After 24 hours, these
were lysed and stored in the same manner as the FOS-treated group. Analysis was done
on an Agilent 7890B Triple Quadrupole (QQQ) GC/MS.
Methylation and detection was done using similar methods as above with
modification. Seven stock solutions of methylated ABA were prepared to a final
concentration of 1000, 500, 250, 100, 50, 25, and 10 nM. Injections of 3.5 µL were injected
into the gas chromatographer using a Zebron ZB-5HT Inferno column (30 m, i.d. 0.25
mm) incubated at an initial oven temperature of 100 °C and heated to a final temperature
of 325 °C at a rate of 20 °C.min-1. The elution of the methylated ABA was determined
using a scan range of 277-282 m/z. All injections were conducted in triplicate and the
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mean and standard deviation calculated.

Analysis was done on an Agilent 7890A

Quadrupole Time-of-Flight (Q-TOF) GC/MS.

13

C-IPP synthesis
Preparation of

13

C Wittig Reagent. A solution of 9.23g (0.035 mol) of

triphenylphosphine was dissolved in 25 mL of anhydrous THF under argon gas in sealed
a round bottom flask and shielded from light. While stirring, 5g (0.035 mole) of 13C methyl
iodide was added dropwise with a syringe and allow to run overnight at room temperature.
The resulting product was rinsed with THF and dried under vacuum with rotary evaporator
yielding 14g (0.0346 mol) of

13

C methyltriphenylphosphonium iodide as a solid white

powder (99% yield). Product was verified using 1H and 13C NMR.
1. Silyl Protection of 4-hydroxybutan-2-one. A solution of 6g (0.088 mole) of
imidazole and 6.3g of tert-butyldimethylsilyl chloride (0.042 mol) dissolved in 15 mL
anhydrous dimethylformamide was added to a 50 mL round bottom flask under argon gas
and sealed with a rubber septum. Solution was stirred and 3 mL (0.035 mole) of
hydroxybutan-2-one was added dropwise under argon using syringe. Reaction was
allowed to run overnight at room temperature and quenched with deionized water.
Product was purified with hexane/water partition in separatory funnel and organic layer
was dried under vacuum with rotary evaporator yielding 7g (0.0345 mole) of silyl protected
alcohol as a clear oil (99% yield). Product was verified using GC/MS (EI) and 1H NMR
(Figure 3.2).
2. Wittig Reaction (Introduction of the

13

C label). A 500-mL three-necked round-

bottomed flask fitted with a reflux condenser, solid addition funnel, and rubber septum
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was sealed, evacuated, and filled with argon gas. 150 mL of anhydrous THF was added
followed by 20 mL n-butylithium (2.5 M in hexanes). While stirring, 10g of

13

C

methyltriphenylphosphonium iodide was added slowly to form the ylide. 5g of silyl
protected alcohol was diluted in THF and added dropwise through a syringe. Reaction
was refluxed overnight at 66 ºC (with argon balloon) and quenched with ammonium
chloride solution. Reaction mixture was extracted with pentane and dried under vacuum
before purification on a silica gel flash column yielding 3.7 g of TBS protected

13

C

isoprenol as a clear oil (75% yield). Product was verified using GC/MS (EI) and 1H and
13

C NMR.
3. Deprotection of Silyl ether. A solution of 50 mL THF and 15 mL pyridine was

prepared in a polypropylene container and 5 mL 48% aqueous HF was added. Solution
was stirred and 3.5g of TBS protected

13

C isoprenol was diluted in THF and added

dropwise, vessel was capped and stirred overnight at room temperature. Reaction was
neutralized with saturated NaHCO3 (aq) and reaction mixture was extracted with
dichloromethane in separatory funnel. Organic layer was washed with 15% CuSO4 and
then 3% HCl to remove pyridine. Product was dried under vacuum and then purified using
silica gel flash column yielding 1.16g of

13

C isoprenol as a clear oil (77% yield). Product

was verified using GC/MS (EI) and 1H and 13C NMR. This was phosphorylated according
to methods outlined in [204].

3

H enzyme activity assay
Plasmodium vivax geranylgeranyl pyrophosphate synthase (PvGGPPS) was

donated by Raymond Hui of University of Toronto. [1-3H] IPP triammonium salt (60
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Ci/mmol) was purchased from American Radiolabeled Chemicals Inc. (ARC 0377A). To
test activity of enzyme, a modified protocol was utilized [205]. 10 µM IPP, 5 µM DMAPP
and 10 nCi 3H-IPP were added to a cocktail buffer containing 100 mM TrisCl (pH 7.7), 4
mM MgCl2, 2 mM TCEP and 5 mg/mL bovine serum albumin (BSA) for a total volume of
100 µL. 100 µg/mL enzyme was added and the reaction was incubated in 37 ºC for an
hour. A sample without enzyme was prepared as a negative control. The reaction was
stopped with 200 µL MeOH/HCl (4:1) and incubated for an additional 10 minutes. 400 µL
pentane was then added, vortexed and centrifuged at 3000 rpm for 5 minutes. 200 µL of
the upper organic phase was collected and added to a 96-well plate. Scintillation fluid was
added upon drying and this was analyzed on a TopCount Scintillation Counter for counts
per minute.

13

C3-GGPP reaction and purification
100 μM

C-IPP and 50 μM DMAPP were incubated in cocktail buffer with 100

13

μg/mL PvGGPPS overnight for 12 hours. This was then flash frozen in liquid nitrogen and
stored in -80 ºC before liquid-chromatography mass spectroscopy (LC-MS) analysis on
an Agilent 6230 LC/MS TOF. Solvent A was 20 mmol ammonium bicarbonate, water and
0.1% triethylamine (TEA). Solvent B was 9:1 acetonitrile/water (ACN/H2O) and 0.1% TEA.
Electrospray (ESI) was done in negative mode with a scan range of 371-471 m/z.
Injection volume was 20 μL with a flow rate of 300 μL/min starting at 2% solvent B for 3
minutes and increased to 99% over 7 minutes. Retention time of analyte was 8.7 minutes.
Reaction without BSA was used for purification on a Shimadzu 10A with SEDEX 75 ELSD
high performance liquid chromatography (HPLC) system. Solvent A was H2O and Solvent
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B was ACN. 400 μL was injected at a flow rate of 1.2 mL/min starting at 15% and
increased to 99% over 10 minutes. Retention time of analyte was 6.8 minutes.

13

C3-GGPP metabolic labelling of P. falciparum
1 mL asynchronous 3D7 culture was incubated in 12-well plates at 2% parasitemia

in 4% hematocrit. 10 μM FOS and 2 μM

13

C3-GGPP were added in addition to 50 μM

FLD, 500 μM sodium tungstate (STS), 500 μM sodium bisulfite (SBS), or 100 μM
naproxen (NAP). A control with 0.1% DMSO and an untreated RBC sample were also
prepared. After 24 hours, the parasites were saponin lysed, washed three times with PBS
and stored in -80 ºC. These were later analyzed with on a Q-TOF GC-MS according to
methods outlined above.

Results
ABA is detected in Plasmodium falciparum extracts
We initially wanted to confirm that ABA is detectable in blood stage parasite
extracts. Without knowing what stage biosynthesis would be at its highest, we started with
an asynchronous W2 culture. Groups consisted of a DMSO control and 50 µM fluridone
(FLD). Parasite extracts were first methylated in order to derivatize the carboxlylic acid (COOH) portion of ABA into its methyl ester due to –COOH being weakly detected on GCMS (Figure 3.3). This changes the expected mass-to- charge ratio (m/z) from 264 to 278
m/z. Nanogram (ng) quantities were obtained with a three-fold reduction in FLD-treated
parasites (Figure 3.4). The experiment was repeated using different antibiotics (Figure
3.5). An untreated red blood cell (RBC) control was also analyzed. ABA was detected in
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our control in larger quantities. There was a significant difference between control and
drug treated groups. ABA content was 40-80 times more abundant in control than those
exposed to drugs. ABA was not detected in RBCs.

Synthesis of 13C-IPP
In order to get GGPP with three 13C labels, it was first necessary to synthesize 13CIPP, the basic isoprene unit which would be used in reactions with unlabeled DMAPP.
13

C-isoprenol was synthesized using a Witting reaction (Figure 3.2). The alcohol group

was exchanged for the pyrophosphate in order to yield our end product, 13C-IPP.

Synthesis of 13C3-GGPP
PvGGPPS was donated and stored in -80 ºC prior to reactions. An assay with 3HIPP was performed to verify activity of enzyme prior to reaction (Figure 3.6). The assay
aims to test if enzyme will form an acid stable product. The rationale behind this comes
from the fact that IPP is nonallylic and stable in acid due to the position of its double bond.
HCl breaks down acid sensitive compounds to their alcohol derivatives which can then
be solubilized in organic solvents such as pentane and hexane. Likewise GGPP is
expected to form geranylgeraniol (GGol) after acid treatment. Counts per minute were
detected in reaction mixture exposed to the enzyme. As expected, no counts were
detected when there was no enzyme, representing a lack of radioactive product
formation.
After the enzyme was confirmed to be active we did a test run to confirm GGPP
production. Initially when scaling up the reaction, the substrate concentrations used were
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1M IPP and 0.5M DMAPP. GGPP was detected but the yield was far less than expected.
This was solved by decreasing the substrate concentrations down to 100 µM 13C-IPP and
50 µM DMAPP (Figure 3.7). We were able to successfully synthesized

13

C3-GGPP and

found extending the reaction time from initially 2 hours to 12 hours had a significant impact
on yield produced.

ABA production in GGPP and IPP rescued parasites
Isoprenoid inhibition of P. falciparum results in parasite death as IPP is an essential
metabolite for survival. A drug like fosmidomycin (FOS) which targets DOXP
reductoisomerase

(DXR), an enzyme early in the isoprenoid biosynthetic pathway,

results in rapid death that is most effective at the ring stages. Exposure to doxycycline
(DOX) reveals a delayed death phenotype that is characterized by death in the second
life cycle. This is due to DOX’s ability to interfere with apicoplast replication such that the
daughter parasites do not have one and therefore are unable to produce IPP.
Supplementation of exogenous IPP is enough to reverse this for both methods of
isoprenoid inhibition [155]. GGPP can rescue FOS-treated parasites but only has
moderate effectiveness with DOX (Chapter 3). We wanted to see if IPP or GGPP rescued
parasites would produce ABA. Parasites were synchronized and treated with FOS or
DOX. IPP and GGPP were given to parasites at the same time as FOS and processed
24 hours later. DOX treated parasites were given IPP and GGPP 48 hours later. This was
done to ensure that they did not have an apicoplast. They were lysed and stored after an
additional 24 hours. Controls were taken at 0, 24 and 72 hours. This would allow us to
see any differences between early form parasites (0H) and later forms (24, 72H).
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Unfortunately analysis was impeded by breakdown of the QQQ GC/MS when we tried to
analyze the samples. Q-TOF was not sensitive enough to accurately quantify ABA at the
low concentrations produced.

Metabolic labeling of P. falciparum with 13C3-GGPP
We aimed to block endogenous isoprenoid production with FOS, which would then
be supplemented with

13

C-GGPP for incorporation into the carotenoid biosynthetic

pathway and ABA. In addition to FLD, carotenoid inhibitors, NAP, SBS and STS were
given to parasites in order to detect an accumulation of intermediates in preceding steps
(Figure 3.1). These three have activity against steps following catabolism to xanthoxin,
which has not been identified in Plasmodium. Unfortunately the QQQ GC/MS used to
detect and quantify ABA in the above experiment went down prior to analysis. A modified
protocol was developed for use on a Q-TOF but our samples fell below the limit of
detection and therefore we cannot make any conclusions about the fate of 13C3-GGPP.

Discussion
By using [1-3H] GGPP as a metabolic label, Tonhosolo et al. biosynthesized
carotenoids which only incorporated two labels into their 40-carbon backbone. In order
for ABA to be made, this is catabolized first into the 15-carbon xanthoxin before
rearrangement into abscisic aldehyde followed by ABA. During this catabolic step, the
label would have been lost and therefore ABA and its preceding intermediates would have
been undetectable. We aimed to circumvent this by taking a different approach involving
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the use of GGPP with three labels of

13

C. Our carotenoids would have incorporated six

labels and two were expected to be retained and detectable in ABA.
The first signs of ABA production in an Apicomplexan parasite was obtained from
T. gondii [163]. We speculated whether it might also be found in Plasmodium. We
detected ABA in blood stage lysates. This was reduced when exposed to FLD, suggesting
that the parasites may have a mechanism for making ABA, which can be blocked with
carotenoid inhibitors. FLD inhibits PDS, the same enzyme that NFZ targets. PDS has
been identified in Plasmodium, so a decrease in a detectable carotenoid catabolite is
consistent with NFZ [158]. Different antibiotics that target the apicoplast reduced ABA
with or without FLD, although those may be secondary effects not specifically due to
inhibiting ABA. CLI and CAM exposure results in a delayed death effect with no significant
decrease in parasitemia during the first life cycle [206]. As such 24 hour treatment
wouldn’t be long enough to remove the apicoplast, although some later forms that had
ruptured and became rings, may have been effected. The decline might also be attributed
to overall decrease in protein synthesis in the organelle.
Unfortunately we were unable to look for ABA in the rescue experiments with
labeled and unlabeled GGPP due to unforeseen breakdown of the QQQ GC/MS. This
equipment has high sensitivity suitable for nanomolar detection. We tried to work up a
protocol on a Q-TOF GC-MS but our samples fell below the limit of detection (Figure 3.8).
In the first rescue experiment with unlabeled GGPP and IPP, ABA appeared to be
detected in all groups. Data was not consistent as the FOS-treated groups had higher
values than those with either isoprenoid. These results were not valid and will need to be
repeated on a more reliable instrument with greater sensitivity.
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In the experiment with
exposed to FOS and

13

13

C-GGPP rescue, we expected to see

13

C-ABA in groups

C-GGPP. A peak corresponding to unlabeled ABA was detected

but the retention time was shifted compared to standard (Figure 3.8). A possible
explanation for this could be attributed to the fact that asynchronous cultures were treated
with FOS. FOS is most active against ring stages and not as effective against later forms
at inhibiting the isoprenoid pathway and causing parasite death. A future consideration
would be to modify the protocol to start with rings but again, a functional QQQ GC/MS
would be necessary to analyze this.
We have not been able to identify candidates for ABA synthesis enzymes. ABAresponse genes have been found in T.gondii and are conserved in Plasmodium as well
[163]. ABA is made via a more direct pathway in fungi, that utilizes farnesyl pyrophosphate
(FPP) as a precursor instead of carotenoids [171]. We don’t expect Plasmodium to utilize
mechanism however as it is a byproduct of the mevalonate pathway which is absent in
Apicomplexans.
Abscisic acid has a global role as a signaling hormone involved in calcium (Ca2+)
release via cyclic ADP-ribose activity. This is conserved across plants, humans, T. gondii,
and sponges [163, 164, 166, 173]. If ABA is produced in Plasmodium, it may have similar
functionality. We’ve established a role of exogenous ABA to dormant parasites (Chapter
2) which differs from endogenous role in plants.
Despite not being able to analyze the label experiments proposed, we cannot rule
out that ABA is synthesized by P. falciparum. Our initial GC-MS data seems promising
and evidence in the form of the carotenoid pathway as well as ABA production in T.gondii
help support this. The use of our

13

C-GGPP with three labels for metabolic labeling in
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Plasmodium is novel and has not been reported in literature. We plan to proceed with this
and expect the label to be incorporated into ABA to confirm the missing part of the
pathway (Figure 3.9). This could have applications to potentially uncover metabolites not
yet characterized in Plasmodium and other organisms.
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Figure 3.1. ABA pathway in plants. ABA is synthesized in plants via the MEP pathway.
It initially occurs in chloroplasts and then shuttled out to the cytosol for completion
Isoprenoid and carotenoid production has been confirmed in P. falciparum but the final
steps starting from the catabolized xanthoxin to ABA has not. Inhibitors are highlighted in
red [207-210].
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Figure 3.2. 13C-Isoprenol synthesis. A Witting reaction was used to incorporate 13C into
isoprenol. This was later phosphorylated to yield a molecule of 13C-IPP.

89

A

B

C

Figure 3.3. Schematic of ABA methylation. (A) ABA standard is methylated with
diazomethane which converts the carboxylic group into its methyl ester. This is achieved
due to the weakly detected carboxylic group on GC. (B) The total ion chromatograph of 2
and (C) the corresponding SIM mass spectrum
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Figure 3.4. ABA is detectable in the blood stages of P. falciparum. ABA is detected
in ng quantities in asynchronous cultures. This was reduced 3-fold when exposed to
carotenoid inhibitor, FLD, for 24 hours.
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Figure 3.5. Antibiotics reduce the levels of ABA detected. ABA was detected and
quantified in lysed parasites. This is reduced when exposed to antibiotics that target the
apicoplast as well as fluridone. CLI = clindamycin; CAM = chloramphenicol; MIR =
mirincamycin; FLD = fluridone; RBC = red blood cell; Statistics were analyzed by oneway ANOVA with Newman-Keuls multiple comparison test; p< 0.05
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Figure 3.6. Enzyme assay schematic. (A) Enzyme is incubated with substrates at 37
ºC. HCl/MeoH is used to stop the reaction and the acid cleaves off the phosphate group
from 3H-GGPP yielding its alcohol derivative, 3H-geranylgeraniol. This was partitioned
with pentane and collected for counts representing radioactive product formed. (B)
Counts per minute were obtained in presence of PvGGPPS. Bars represent ± SEM
E= enzyme, S = substrate, P = product
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Figure 3.7. 13C3-GGPP detection on LC-MS. 13C3-GGPP was detected on LC-MS.
Retention time was 8.7 min and corresponding mass was 452.1802.
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Figure 3.8. FOS + 13C3-GGPP sample compared to ABA standard. A broad peak was
observed with a mass representing unlabeled ABA. There was a shift in retention time
compared to standard. One potential explanation for unlabeled ABA is FOS was given to
a mixed culture which had later forms that are less susceptible to the drug than rings. The
Q-TOF is also not sensitive enough to accurately detect low quantities and samples fell
below limit of detection
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Figure 3.9. Proposed pathway for ABA biosynthesis in P. falciparum. 13C-IPP
condenses with DMAPP to form 13C3-GGPP. This feeds into carotenoid biosynthesis and
we expect the fate of two labels to be incorporated into ABA, abscisic aldehyde and
xanthoxin. Stars represent 13C label.
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Table 3.1. Carotenoid inhibitor IC50s against 3D7
Inhibitor
Abbreviation
IC50 (µM)
CLZ
249.7
Clomazone
FLD
60.3 ± 3.04
Fluridone
ISF
91.9 ± 29.17
Isoxaflutole
Naproxen
Nicotine
Norflurazon
Sodium bisulfite
Sodium tungstate
Sulcotrione

NAP
NIC
NFZ
SBS
STS
SUL

99.6 ± 0.34
46.6 ± 6.4
36.6 ± 23.3
> 500
> 500
128.9 ± 72.3

Target
Doxp synthase
Phytoene desaturase
4-hydroxyphenylpyruvate
dioxygenase (HPPD)
Lipoxygenases
N/A
Phytoene desaturase
ABA aldeyhyde oxidase
Xanthoxin dehydrogenase
HPPD

IC50s for several carotenoid inhibitors against 3D7. Target represents enzymes in plants
that are inhibited.
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Chapter 4
Synthesis of 13C3 geranylgeranyl pyrophosphate with Plasmodium and
human geranylgeranyl pyrophosphate synthase

Abstract
Plasmodium vivax geranylgeranyl pyrophosphate synthase was previously cloned
and its crystal structure and activity was characterized. It was found to be able to catalyze
production of geranylgeranyl pyrophosphate (GGPP) from 5, 10 and 15 carbon
isoprenoids. We intended to use this to synthesize 13C3-GGPP with three labels in order
to metabolically label carotenoid precursors and characterize the abscisic acid
biosynthetic pathway. Outlined here is work done to optimize expression and purification
of this enzyme. A human variant of the enzyme was also used to optimize efficient
reaction conditions.

Introduction
Plasmodium vivax geranylgeranyl pyrophosphate synthase (PvGGPPS) belongs
to a family of protein transferases that catalyzes the reaction of geranylgeranyl
pyrophosphate GGPP using isopentyl pyrophosphate (IPP) and allylic primers such as
dimethylallyl pyropsphophate (DMAPP), geranyl pyrophosphate (GPP) or farnesyl
pyrophosphate (FPP) [205]. The enzyme appears to be bifunctional as it shares homology
with human GGPPS but is more closely related to farnesyl pyrophosphate synthase
(FPPS) [205]. Despite this, it is more effective at producing GGPP. N-alkyl
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bisphosphonates, which inhibit GGPPS and FPPS, have potent activity against
Plasmodium parasites highlighting the importance of their activity for parasite viability
[211]. GGPP plays an important role as one of the main isoprenoids involved in
posttranslational modification of proteins. GGPP covalently binds to GTPases in other
systems to switch on different biochemical pathways [212]. Protein prenylation is
essential in P. falciparum as inhibition decreases parasite growth. GGPP also forms the
building blocks of carotenoid biosynthesis which has been established in P. falciparum
[158]. More recently a P. falciparum enzyme, PfFPPS (PF3D7_1128400) has been
cloned and characterized for its bifunctional activity in producing FPP and GGPP [213].
In chapter 2, we established that GGPP can reverse the effects of fosmidomycin
inhibition. We aimed to exploit this by using

13

P. falciparum. The initial goal to synthesize

C3-GGPP to confirm ABA biosynthesis in

13

C3-GGPP involved using PvGGPPS to

catalyze the reaction of 13C-isopentyl pyrophosphate (13C-IPP) and DMAPP. Challenges
were faced that resulted in switching to HsGGPS1 for additional optimization of reaction
conditions. Ultimately we ended up using PvGGPPS after conditions had been properly
optimized and good yield was obtained. Here is work done to express, purify and optimize
conditions of the enzyme.

Materials and Methods
Small-scale expression of Plasmodium vivax geranylgeranyl pyrophosphate
(PvGGPPS)
Plasmid containing PVX_092040 which encodes for P. vivax protein was donated
by Raymond Hui of University of Toronto. This contains an N-terminal His6 tag and TEV
cleavage site (MGSSHHHHHHSSGRENLYFQ*G). Expression was modified from [214].
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This was transformed with E. coli BL21-CodonPlus (DE3)-RIL competent cells (Agilent #
230245). 2 µL of 1:10 XL1-Gold β-mercaptoethanol was added to 100 µL cells and kept
on ice for 10 minutes. About 40 ng DNA was added to this mixture and incubated on ice
for an additional 30 minutes. Cells were heat-pulsed in a 42 ºC water bath for 20 seconds
and then placed on ice for 2 minutes before being transferred to a 5 mL chilled falcon
tube. 500 µL preheated SOC media was added to the tube. This was incubated at 37 ºC
and shaken for 1 hour. 50 µL was used to streak an agar plate containing Luria-Bertani
(LB) with 34 µg/mL chloramphenicol (CAM) and 100 µg/mL ampicillin (AMP). This was
left to incubate at 37 ºC overnight. One colony from the agar plate was chosen to inoculate
3 mL LB media containing AMP and CAM and incubated overnight at 37 ºC. The cultures
were diluted 1:10 in 5mL LB media and shaken at 250 rpm at 37 ºC until OD600 reached
0.80. At this point 1M isopropyl-β-d-thiogalactopyranoside (IPTG) was added and the
cultures were moved to 22 ºC for 8 hours.
Protein expression was verified by western blot. An aliquot was run on a 10% SDSPAGE gel and transferred to nitrocellulose. This was blocked for 1 hour with 10% milk
(in PBS-Tween 20) and incubated overnight at 4 ºC with mouse 6x-His tag antibody
(Invitrogen, #37-2900). This was washed three times with PBS-Tween 20 and incubated
with1:3000 dilution of peroxidase-conjugated AffiniPure Goat anti-mouse IgG conjugated
antibody for 1 hour following 3x wash. ECL reagent (GE Healthcare) was added and thr
blot was imaged on a Konica Minolta SRX-101A x-ray developer.
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Large scale expression of PvGGPPS
E. coli was grown overnight at 37 ºC in 100 mL LB media. On the following day,
25 mL was added to 470 mL terrific broth (TB) media consisting of 90% TB medium and
10% potassium phosphate buffer (0.17M KH2PO4 and 0.72M K2HPO4). 5 mL of trace
elements [200 mM FeCl3.6H2O, 95 mM ZnSO4.7H2O, 19 mM MnCl2.4H2O, 3 mM
CuSO4.5H20, 9.7 mM H3BO3, 2.7 mM CoCl2.6H2O, 10 mM Na2MoO4.2H2O, 5% HCl
(12N)] was added and this was shaken at 37 ºC until OD600 = 0.80. 1M IPTG was added
and left to shake for 8 hours at 22 ºC. This was centrifuged and the supernatant removed.
Pellet was resuspended in 20 mL binding buffer (500 mM NaCl, 5% glycerol, 50 mM
HEPES, pH 7.5, 5mM imidazole) with protease inhibitor cocktail [100 mM benzamadine
HCl, 1 mM phenylmethylsulfonyl fluoride (PMSF)] and frozen at -80 ºC.

Purification of PvGGPPS
Pellet was thawed at 4 ºC overnight on day prior to purification. 0.5% CHAPS, 200
µg/mL lysozyme and 50 µg/mL DNAse were added to the suspension and mixed for 40
minutes at 4 ºC. This was sonnicated three times on ice and centrifuged for 20 minutes
at 15,300 rpm at 4 ºC. Binding buffer was equilibrated with Ni Sepharose 6 Fast Flow
resin (GE Healthcare Life Sciences, # 17-5318-02) at room temperature. The suspension
was separated from pellet and added to the resin which was mixed for 1 hour at room
temperature. This was centrifuged and washed three times with wash buffer (500 mM
NaCl, 5% glycerol, 50 mM HEPES, pH 7.5, 30mM imidazole). The resin was added to a
column and eluted with elution buffer (500 mM NaCl, 5% glycerol, 50 mM HEPES, pH
7.5, 250 mM imidazole) in 10 aliquots of 1 mL. 1M dithiothreitol (DTT) was added
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immediately followed by 0.5 M ethylenediaminetetraacetic acid (EDTA), 15 minutes later.
Concentration was obtained on a NanoDrop Spectrophotometer (ND-1000), and protein
was evaluated on a 10% SDS-PAGE gel. Protein was stored in -20 ºC until use.

Initial expression and purification
The plasmid was initially transformed under a different protocol with the following
modifications that differed from above in BL21 DE3 pLys E. coli and expressed in LB
broth which was verified with western blot. Lysate was stored at -80 ºC with DNAse and
lysozyme in solubilizing buffer (8M urea, 20 mM sodium phosphate, 10 mM imidazole, pH
7.8) prior to purification. After equilibration with Ni-NTA resin (Qiagen, #1018244), this
was washed with wash buffer (8M urea, 20 mM sodium phosphate, 10 mM imidazole, pH
7.8). This was eluted on a column with elution buffer (8M urea, 350 mM imidazole, pH
7.8). Protein was evaluated with 10% SDS-PAGE gel.

Enzyme activity assays
Enzyme activity of PvGGPPS was initially tested with 14C-IPP based off a previous
described protocol [205]. [1-14C] IPP triammonium salt (55 mCi/mmol) was purchased
from American Radiolabeled Chemicals Inc. (ARC 0541) 100 µL reaction tubes were
prepared containing 50 or 250 µg/mL PvGGPPS and buffer with final concentration of 50
mM Tris, 2mM MgCl2, 1mM TCEP, 5 mg/mL bovine serum albumin). Substrates 10 µM
IPP, 5 µM DMAPP, 5 µM FPP and 10 nCi 14C-IPP were added according to Table 4 and
incubated at 37 ºC. After a set time, reactions were stopped with 200 µL HCl/MeOH (1:4)
and incubated for an additional 10 minutes. 400 µL pentane was then added, vortexed
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and centrifuged. 200 µL of the upper organic layer was collected for reading on a
scintillation counter. Recombinant human GGPS1 (HsGGPS1) protein was ordered from
Abcam (catalog # ab100959). Comparison reactions to HsGGPS1 were done in a similar
manner using 10 nCi 3H-IPP with 1 and 10 µg/mL enzyme concentration.
3

H-geranylgeranyiol product was verified by thin layer chromatography (TLC). A

30 minute reaction was set up with 250 µg/mL PvGGPPS. 450 µL pentane was added
after HCl/MeOH and 350 µL was collected. 35 µL was then counted on a scintillation
counter. The remaining liquid was dried down with nitrogen and 10 µL hexane was added.
1 µL was spotted on a silica plate alongside farnesol (5 µg/mL) and geranylgeraniol (10
µg/mL) standards. Mobile phase was ethyl acetate/toluene (1:3). The plate was sprayed
with En3hance (Perkin Elmer) and placed in an autoradiograph cassette for three days
before transferring to X-ray.
A modified protocol was performed with 100 µg/mL PvGGPS with 750 nmol IPP
and 75 nmol DMAPP in 850 nmol potassium phosphate (K+) buffer (pH 7.0) and 85 nmol
MgCl2 [215]. After incubation at 37 ºC for one hour, MeOH was added to make a final
mixture of 10%. This was run through a Sep-Pak tC18 vac cartridge (Waters, #186004618)
that had been prewashed with 100% MeOH followed by 10% MeOH. Drop through was
collected, followed by wash with 10% MeOH. Product was eluted with 90% MeOH. After
drying with a Speedvac, these were spotted on a silica plate to verify GGPP by TLC
analysis.
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GGPP synthesis and quantification
GGPP was synthesized, analyzed and quantified according to methods outlined in
Chapter 3.

Results
Enzyme expression and purification optimization
The plasmid was originally expressed and purified under a different protocol which
yielded insoluble protein that formed inclusion bodies. Expression was modified after
using BL21-CodonPlus (DE3-RIL) E. coli for transformation. Our protein of interest was
43 kDa (46 kDa with TEV cleavage site) and was detectable at around the 50 kDA mark.
Lower weight fragments were detected, suggesting there may have been some slight
degradation. E. coli from Lane 4 was chosen for further growth and expression as it
exhibited the least amount of degradation (Figure 4.1A). Optimization conditions were
performed as outlined in Figure 4.1B. Expression seemed to be slightly higher with TB
media although a significant difference wasn’t observed between groups (Figure 4.1C).
22 ºC, 1 mM IPTG for 8 hours was chosen as expression conditions. Enzyme was soluble
and purified with Ni Sepharose 6 Fast Flow resin (Figure 4.2)

Purified PvGGPPS is active and produces GGPP
Enzyme activity was first verified using 3H-IPP in reactions with IPP and DMAPP
or FPP (Figure 4.2A). Except where noted, all were run for 30 minutes. Increased counts
per minute (CPM) were observed when time was extended. The highest CPM was in
reaction without cold IPP. This was expected as all IPP used to make GGPP were
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radioactive and not diluted with nonradioactive substrate. Using FPP as a substrate also
yielded higher counts at 30 minutes. This is likely do to fast reaction because FPP
contains 15 carbons. This requires only one isoprene unit to make GGPP, as opposed to
DMAPP needing three. The kcat value with FPP is 0.8 s-1 vs 0.5 s-1 with DMAPP [205]. No
CPM were obtained at time 0, and reactions with no enzyme or DMAPP. This was all
expected and confirmed validity of the assay. Without an allylic primer, such as DMAPP
or FPP, the enzyme cannot make GGPP. In order to verify that the product being
synthesized is GGPP, TLC was run. After acid treatment to form 3H- GGol, this was
spotted on TLC (Figure 4.3B). The sample matched standard and this radioactive product
was visible on an autoradiograph.
This reaction was done in K+ buffer and spotted on TLC, but was weakly detected
(Figure 4.4). GGPP was undetectable when analyzing on LC-MS. We suspected that
interference from the phosphates in the K+ buffer for the nonradioactive reaction may be
causing interference. A comparison reaction was performed using 3H-IPP and 50 µg/mL
enzyme for one hour in both types of buffers (Figure 4.5). The reactions were significantly
different. All reactions to synthesize GGPP were conducted in Tris based buffer following
these results.

13

C-GGPP synthesis with HsGGPS1 and PvGGPPS1
Despite changing buffer conditions for nonradioactive reaction, GGPP remained

undetectable when analyzing reaction mixtures on LC-MS. Human GGPPS (HsGGPS1)
was purchased and used in reactions. A comparison reaction assay was set up using 1
and 10 µg/mL of PvGGPS or HsGGPS1 (Figure 4.6). Counts were higher with HsGGPS1
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under both conditions. GGPP reaction was conducted with 1 and 10 µg/mL HsGGPS1
with IPP (1000 µM) and DMAPP (200 µM) for 2 hours. This was analyzed on LC-MS and
we were able to detect low yields of GGPP. We were also able to detect 13C3-GGPP when
13

C-IPP (1000 µM) and DMAPP (333 µM) was used (Figure 4.7). LC-MS revealed a value

of 452.1967 m/z compared to 449.1896 m/z for GGPP standard, representing a shift by
the three

13

Cs. After reducing

13

C-IPP concentration down to 100 µM and altering the

ratio of DMAPP used as well as length of reaction we were able to increase yield (Figure
4.8). 50 µg/mL HsGGPS1 with

13

C-IPP (100 µM) and DMAPP (50 µM) for 12 hours was

determined to be the best working conditions for the reaction (Figure 4.9).
With working conditions optimized for HsGGPS1, we ran reactions with PvGGPS
adjusting enzyme concentration and reaction time (Table 4.2). The most

13

C3-GGPP

seemed to be produced with 100 µg/mL HsGGPS1 for 6 hours. Surprisingly calculated
concentration obtained were higher in PvGGPPS reactions than HsGGPS1 reactions.

Discussion
E. coli as expression vectors are useful for production of recombinant proteins.
They are easily malleable to transformation with plasmids containing genes for protein of
interest. Growth and expression conditions however vary greatly from protein to protein
as well as the vector. Optimization requires finding the right set of conditions that will
maximize yield and make purification simple. The original protocol that was used to
express and purify the protein yielded insoluble material. The protein was detectable via
western blot but would not properly elute in the buffers used. Switching from a phosphate
based buffer to HEPES based buffer with slightly lower pH resulted in soluble protein that
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was easily eluted. When optimizing conditions for efficient expression, thicker bands were
observed with E. coli cultured in TB media. These were supplemented with trace elements
which enhanced growth and improved expressions. There wasn’t however any significant
difference observed when altering temperature or length of expression. There was
sometimes fragmentation detected at the 64 and 37 kDa mark. This potentially may have
been due to degradation and/or aggregation of protein.
After verifying activity to synthesize GGPP with the radiolabeled IPP assays, eluted
product was spotted on a TLC. We were able to detect faint band for GGPP but this was
not consistent. Often unreactive IPP would be detected suggesting there was something
wrong with our reaction. At first it seemed it may have been the K+ buffer used for the
reaction. To verify this theory, a comparison assay was done with 3H-IPP and counts were
higher with Tris buffer. Unfortunately that did not solve the problem as GGPP was
undetectable in LC-MS as well as NMR (data not shown). Following these challenges, we
switched to a human variant as Plasmodium specific enzyme was not needed for the
reaction.
We initially attempted to run the reaction with HsGGPS1, 1M IPP and 0.5M
DMAPP. GGPP was detected but recovered yield was under 1% (data not shown). We
learned this was due to potential substrate inhibition. Kavanaugh et al. reported that there
is no substrate inhibition up to 100 µM of IPP [216]. After reducing both IPP and DMAPP
to 100 and 50 µM, the recovered GGPP yield increased. This explained why the enzyme
assays worked as those were done with 10 and 5 µM substrates, which were too low to
cause any inhibition. We scaled up to increase GGPP yield, not realizing this had a
negative effect on production.
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While keeping the concentration of IPP at 100 µM, reactions were done with
DMAPP at concentration ranges from 20, 33, 50 µM). The highest yield was obtained
when they were in a 2:1 ratio (Figure 4.9). When this was scaled up to 2 mL and ran
overnight for 12 hours, the concentration significantly increased. After good reaction
conditions were determined with HsGGPS1, we tried to optimize GGPP production with
PvGGPPS. The values were higher when compared with HsGGPS1 in the assays with
radiolabeled IPP. The differences in substrates may affect efficiency of the enzymes with
lower substrates yielding higher yield with HsGGPS1 as opposed to PvGGPPS.
After reducing the substrate concentrations, the reaction was repeated and purified
on LC-MS. Upon drying however, crystals formed with the product and the mass was
larger than expected. We deduced that it was due to BSA (5 mg/mL) used in the buffer.
GGPP was being bound to the albumin and was the reason why we were unable to purify
it. The reaction was repeated again with PvGGPS, without BSA, and crystals did not form
so we were able to purify product. There was potential product inhibition that was reduced
by the presence of BSA and removing it led to lower yields of GGPP. The

13

C3-GGPP

that was recovered was used in the experiments outlined in Chapter 3.
GGPPS represent enzymes that synthesize important GGPP that is essential for
protein prenylation, carotenoid biosynthesis and other terpenes across a large variety of
living organisms. We previously showed that GGPP supplementation can reverse the
effects of fosmidomycin inhibited isoprenoid biosynthesis in the erythrocytic stages of P.
falciparum (Chapter 2), highlighting an important role it plays in parasites viability.
Following PvGGPPS expression and purification, we were able to synthesize 13C3-GGPP.
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This can be used in metabolic labeling of isoprenoid products to identify unknown
metabolites and further elucidate incomplete biochemical pathways.
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Figure 4.1. Expression optimization. (A) 4 separate colonies were selected from agar
plate and expression as induced. E. coli from lane 4 was chosen for further expression
due to least fragmentation in western blot. (B) PvGGPPS expression optimization is
summarized. (B) SDS gel of whole lysate following IPTG. Expression conditions chosen
were TB media, 22 ºC, 1 mM IPTG for 8 hours. * Lane 3 received 1.5 mM IPTG
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Protocol 1

Protocol 2

Figure 4.2. Purification of PvGGPPS. 46 kDA PvGGPS (with TEV cleavage site) was
expressed and detected in E. coli induced with IPTG and purified using two methods. This
is a comparison of 10% SDS gels of 2nd protocol versus 1st protocol which yielded
insoluble protein.
I = induced; UI = uninduced; BB = before binding; AB = after binding; E = elution
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Figure 4.3. Confirmation of PvGGPPS activity using 14C-IPP. (A) Radioactive counts
representing reaction product were obtained. This was increased in a time dependent
manner. (B) In a separate reaction 3H-IPP was used. TLC and an autoradiograph were
used to confirm that 3H-geranylgeraniol was the product that was created.
F = farnesiol, S= sample, GG = geranylgeraniol
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Figure 4.4. GGPP was detected via TLC. GGPP reaction product was eluted with 90%
MeOH on a Sep-Pak C18 cartridge following small scale reaction. GGPP was visible in
lane 3 compared to GGPP standard. Lanes 1 = drop through, 2 = wash, 3 = eluate,
4 = GGPP standard (3 µg), 5 = Citr-P
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Figure 4.5. PvGGPPS is more active in Tris buffer. Reaction with 50 µg/mL PvGGPPS
was conducted with 3H-IPP for 1 hour. Significantly more counts were obtained in Tris
buffer vs K+ buffer. One-way ANOVA was performed for statistical significance. Bars
represent ± SEM
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Figure 4.6. HsGGPS1 is more active than PvGGPPS. Comparison of PvGGPPS
activity to HsGGPS1 revealed that HsGGPS1 is more active. This is most pronounced
when 10 µg/mL enzyme was used per reaction. Bars represent ± SEM
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Figure 4.7 Substrate inhibition of HSGGPS1 led to reduced 13C3-GGPP production
13
C3-GGPP was detected but at very low quantity. This was due to substrate inhibition
that was interfering with enzyme activity at high concentrations. Arrows represented
contamination in column that was also present in blanks
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Figure 4.8. 13C3-GGPP yield is increased with lower substrate concentration. More
GGGPP was synthesized when the concentration of IPP:DMAPP were reduced from
1000:500 µM to 100:50 µM. This reaction was done using 50 µg/Ml HsGGPS1 for 2 hours.
Arrows represented contamination in column that was also present in blanks
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Reaction
A
B
C
D

13

C-IPP (µM)
100
100
100
100

DMAPP (µM)
20
33
50
50

Time (hour
2
2
2
12

Yield (µM)
0.9
1.0
1.6
14.3

Figure 4.9. HsGGPS1 reaction optimization. Decreasing the ratio of IPP:DMAPP from
5:1 to 2:1 led to increased 13C3-GGPP in reactions. This was also enhanced by extending
the time from 2 to 12 hours.
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Table 4.1 : 14C-IPP PvGGPPS reactions
Contents

1

2

3

4

5

6

7

IPP

+

+

+

+

+

+

+

DMAPP

+

+

+

+

+

-

-

FPP

-

-

-

-

-

-

+

14

+

+

+

+

+

+

+

PvGGPPS +

+

+

-

+

+

+

C-IPP

Reactions 4 and 5 served as negative controls with no enzyme or DMAPP, respectively.
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Table 4.2 : Enzyme reaction optimization
Reaction

Enzyme

Concentration

13

C-IPP

DMAPP

Time

Yield

(µg/mL)

(µM)

(µM)

(hours)

( µM)

A

PvGGPPS

10

100

50

3

6.71 ± 6.2

B

PvGGPPS

50

100

50

3

19.7 ± 11.8

C

PvGGPPS

100

100

50

3

30.64 ± 2.06

D

PvGGPPS

10

100

50

6

15.2 ± 15.6

E

PvGGPPS

50

100

50

6

27.2 ± 8.9

F

PvGGPPS

100

100

50

6

30.5 ± 7.5

G

PvGGPPS

10

100

50

12

18.4 ± 23.3

H

PvGGPPS

50

100

50

12

22.1 ± 17.5

I

PvGGPPS

100

100

50

12

10.5 ± 10.6

J

HsGPPS1

50

100

50

3

12.2 ± 1.9

K

HsGPPS1

50

100

50

6

15.5 ± 2.6

L

HsGPPS1

50

100

50

12

18.8 ± 2.0

Average and SEM. from two independent runs
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Chapter 5
Summary

Despite tremendous efforts to eliminate malaria, it continues to pose a significant
global threat. Artemisinin-based combination therapies have represented an effective
form of treatment which is now threatened due to emerging resistance that echoes an all
too familiar pattern of past antimalarials. A more comprehensive understanding behind
the underlying mechanisms behind how parasites are able to tolerate drug pressure and
develop resistance formation is essential.
The concept of dormancy can partially offer some insight into what may promote
the viability of resistant parasites. Most antimalarials gain their activity by interfering with
essential metabolic processes and/or introducing toxins that are harmful. This is the case
with chloroquine which interferes with breakdown of toxic heme as well as atovaquone
which disrupts pyrimidine biosynthesis [73]. Growing parasites are susceptible to
damage. By arresting growth and shutting down most metabolic activity, dormant forms
are able to exist in the presence of drug and are effectively protected from the harmful
effects that may otherwise kill them. Removal of drug exposure allows them to exit this
state and resume their growth as detectable levels of parasitemia rises.
In this study we explored the effects of the two primary dormancy regulating
hormones of higher plant species for their effect on dormancy induced by a prominent
antimalarial. While they share antagonist roles in plants, that didn’t appear to be the case
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with P. falciparum. Parasites exhibited similar responses when exposed to both GA and
ABA. Recovery was stimulated and we observed parasites exit dormancy earlier than
non-treated groups. They occurred via an unknown mechanism and additional work will
need to be conducted in order to elucidate how GA and ABA mediated recovery. Some
potential theories could be the answers but further research could that. ABA’s role as a
global Ca2+ signaler across a wide range of organisms, including T. gondii, might be
conserved in Plasmodium. This may signal pathways and stimulate mechanisms that are
used in the recovery process of dormant parasites. ABA has been able to influence mRNA
expression and GA is theorized to activate enzymes that mediate the release from
dormancy in seeds [122, 169, 217]. Any effect on expression of enzymes and
upregulation of key genes involved in recrudescing might be identified by monitoring the
response to the phytohormones.
FLD is an effective inhibitor of carotenoid biosynthesis that reduces ABA in plants
and releases seeds from dormancy. This has not been retained in Apicomplexan
parasites as it induces formation of dormant bradyzoites in T. gondii and prolongs
dormancy in P. falciparum. Exposure to it didn’t induce dormancy in P. falciparum but it
had a negative effect on growth and progression through the life cycle was slow. If ABA
is in fact being synthesized by dormant parasites and this is used in the recovery process,
FLD’s block could help explain why exposure to it prevents recrudescence.
Resistance often forms due to treatment incompliance. This is seen in patients that
do not take antimalarials as recommended, especially if symptoms have subsided.
Finding a mechanism to release dormancy is a potential way circumvent this form of drug
evasion. By accelerating recrudescence, parasites become vulnerable and susceptible to
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antimalarials more rapidly. This could be of special importance if the same phenotype is
observed in liver stage dormancy of P. vivax hypnozoites which have limited antimalarials
that are effective against them. Relapses could be prevented by “waking” those dormant
forms up and hitting them with antimalarials that are effective against growing forms.
We’ve known of the apicoplast’s importance for parasite survival but its role in
dormancy has not been reported. It is responsible for biosynthesis of essential
isoprenoids and IPP alone can cause recovery in parasites that have all apicoplastrelated metabolism shut down in parasites that do not have the organelle. There is
skepticism in the science community in regards to dormancy but we show that parasites
without an apicoplast fail to recover but this can be reversed if IPP is supplemented 8
days after inducing dormancy. It is unknown whether IPP is directly needed to recrudesce
or several of its byproducts are key to exiting dormancy. It is likely that no one metabolite
is responsible and it may be a consorted effort between many. GA nor ABA were able to
stimulate recovery alone, but neither are sufficient enough to reverse the effects of
doxycycline and sustain parasite viability.
In this study, we aimed to use

13

C3-GGPP to characterize ABA as well as

carotenoid catabolites leading to its biosynthesis. The data from the experiments
unfortunately were not able to be properly analyzed due to the unexpected malfunction
of vital equipment. Nonetheless, synthesis of this metabolic label is important as it may
have broader utilization beyond the carotenoid pathways. We successfully showed
biosynthesis of

13

C-GGPP with three labels which may have significant applications

beyond this project. Our focus was on one specific portion of a known pathway but there
may be off products that could be labeled that we were not looking for. This novel
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approach may be useful in further characterizing pathways and identifying isoprenoid
products that have not been established in Plasmodium and other organisms.
In summary we have established a role for phytohormones in dormancy induced
in the erythrocytic stages of P. falciparum. The apicoplast and isoprenoids it produces are
essential for recovery. These findings further expand our knowledge about how an
evolutionary link to plant biology is relevant to Plasmodium and a survival mechanism
that both undergo in early developmental stages. Dormancy contributes to antimalarial
resistance and these findings might reveal insights into how that might be regulated
and/or manipulated. Although ABA biosynthesis was not confirmed, there is strong
evidence to suggest that parasites produce it and we cannot conclude that it does not.
13

C3-GGPP has successfully been synthesized from purified PvGGPPS and a method for

detection of 13C-ABA has been established. Confirmation of biosynthesis would introduce
new questions such as do parasites create it as a response to stress? Does endogenous
ABA regulate dormancy? What role might it play in resistance development? These will
be important to know going forward and future work will need to be conducted in order to
answer them as well as validate ABA as an end product of carotenoid biosynthesis in P.
falciparum.
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Appendix A: Additional Figures
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Figure A.1. FLD supplementation over 2 life cycles. 50 uM FLD resulted in parasites
that progressed through the blood stages and a slower rate than control
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Figure A.2. ABA supplementation over 4 life cycles. ABA was supplemented to 3D7
over 4 life cycles and relative luminescence units were obtained daily. ABA had no impact
on growth although reduced numbers were observed with 500 µM after 168 hours. This
was done with AB+ human plasma.
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Figure A.3. GGPP Standard curve. This was the calibration curve done to calculate
GGPP concentration obtained from reactions.
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